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1. Zusammenfassung 
 
Das Varicellazoster-Virus (VZV) gehört zur Unterfamilie der Alphaherpesviren und ist 
mit einem Genom, das für nur 70 Proteine kodiert, das kleinste aller 
humanpathogenen Herpesviren. Die primäre Infektion etabliert sich meist bei Kindern 
als Varizellen bzw. Windpocken. Infolge dessen erreicht das Virus Ganglien 
sensorischer Nerven, wo es latent verbleibt. Bei Reaktivierung kommt es vor allem 
bei Erwachsenen zu einer Sekundärerkrankung, dem sogenannten Herpes Zoster. 
Mangels zellfreien Virus in Zellkultur, Virus-spezifischer Werkzeuge und eines 
effektiven Tiermodells gehört VZV zu den am wenigsten untersuchten humanen 
Herpesviren. Zahlreiche Aspekte des VZV-Replikationszyklus, der Latenz und der 
Reaktivierung sind deshalb wenig charakterisiert. Ausserdem konnte die Funktion 
vieler VZV-spezifischer Proteine bisher nicht identifiziert werden.  
Das Ziel dieses Ansatzes war es, Hybridoma-Zelllinien als permanente Quelle von 
VZV-spezifischen Antikörpern zu etablieren und mit den gewonnenen Antikörpern die 
Lokalisierung von VZV-Proteinen im Viruskontext proteomweit zu untersuchen. Dazu 
wurde mittels der Gateway® Rekombinationstechnologie eine ORFeom-weite Entry-
Bibliothek aller VZV-Gene hergestellt. Zur Proteinexpression in E. coli wurde die 
Entry-Bibliothek in vier verschiedene Expressionsvektoren der pET-Reihe umkloniert, 
die entweder für ein N-terminales His6-, ein C-terminales His6-, ein N-terminales 
MBP- oder ein N-terminales GST-Tag kodieren. Mäuse wurden mit 64 erfolgreich 
gereinigten VZV-Proteinen immunisiert und anschliessend zur Hybridomaherstellung 
verwendet. Die Klonkollektion besteht derzeit aus 218 Mutterklonen, die Antikörper 
gegen 61 (87%) VZV-Proteine produzieren. Dabei waren 190 Klone, die insgesamt 
57 VZV-Proteine erkennen, im Westernblot reaktiv, während 123 gegen 52 VZV-
Proteine gerichtete Antikörper in der Immunfluoreszenz positiv waren. 
Mit Hilfe dieser neuen Antikörper-Kollektion konnte die Lokalisierung von 52 (74%) 
Proteinen, 22 davon zum ersten Mal, im Kontext der VZV-Infektion untersucht 
werden. Insgesamt waren 20 ORFs im Zellnukleus, 16 ORFs im Cytoplasma und 16 
ORFs in beiden Kompartimenten lokalisiert. Der Vergleich von 41 Core-Orthologen, 
die sowohl in HSV-1, VZV, CMV, EBV als auch KSHV vorkommen, hat eine 
ausgezeichnete Űbereinstimmung in der Lokalisierung von konservierten 
Glykoproteinen, Capsid- und Tegumentproteinen gezeigt. Mittels der Pepscan-
Methode konnten auf den viralen Glykoproteinen gK, gB, gL, gI, gE und dem 
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membran-assoziierten Phosphoprotein ORF24 einige immundominante Regionen 
identifiziert werden. Diese kostbare Antikörper-Kollektion kann in mehreren 
methodischen Ansätzen genutzt werden und wird es ermöglichen, biologischen 
Rätseln im Bereich der Herpesvirologie auf die Spur zu kommen. 
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1. Summary 
 
Varicella zoster virus (VZV) is a member of the alphaherpesvirus subfamily and with 
a genome encoding 70 proteins the smallest of all human herpesviruses. Upon 
primary infection it causes varicella also called chickenpox in children. As a 
consequence, it reaches sensory nerve ganglia where latency is established. Upon 
reactivation it causes a secondary disease called Herpes zoster mostly in adults. 
Todate, VZV is the least studied human herpesvirus due to the lack of cell-free virus 
in culture, of virus-specific tools and an effective animal model. Therefore, many 
aspects of the VZV infection cycle, of latency and reactivation are poorly 
characterized. Moreover, the function of many proteins specific to VZV has not been 
identified. 
The goal of this research was to generate hybridoma clones as a permanent source 
of VZV specific antibodies and to use the antibodies produced to study the 
localisation of VZV proteins in the viral context on a proteome-wide level. To this end, 
a VZV ORFeome entry library was constructed using the Gateway® recombinational 
cloning technology. For VZV protein expression in E. coli, the entry library was 
subcloned into four different pET derived expression vectors providing either an N-
terminal His6, a C-terminal His6, an N-terminal MBP, or an N-terminal GST tag. 
Following purification of 64 VZV proteins, mice were immunised and subsequently 
used to generate antibody producing hybridoma clones. So far, our clone collection 
contains 218 mother clones producing antibodies to 61 (87%) VZV proteins. In this 
clone collection 190 clones were identified as positive in Western blotting covering 57 
VZV ORFs while 123 antibodies were tested positive in immunofluorescence 
covering 52 VZV ORFs.  
Using this novel antibody collection, the localisation of 52 (74%) proteins could be 
determined in the context of VZV infection 22 of which were analysed for the first 
time. In total, 20 ORFs were localised in the nucleus, 16 ORFs were present in the 
cytoplasm and 16 ORFs were found in both the nucleus and cytoplasm. Comparison 
of 41 core proteins present in HSV-1, VZV, CMV, EBV as well as KSHV showed 
excellent agreement in localisation of conserved glycoproteins, capsid and tegument 
proteins. Several immunodominant regions on the viral glycoproteins gK, gB, gL, gI, 
gE and the membrane associated phosphoprotein ORF24 were identified using the 
pepscan technique. This precious antibody collection gives access to various 
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experimental approaches and will allow to unveil biological secrets in the field of 
Herpesvirology. 
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2. Introduction 
 
2.1 Herpesviridae 
Herpesviruses are linear double-stranded (ds) DNA viruses that cause diseases in 
animals, including humans. The family name is derived from the greek word herpein 
("to creep"), referring to latency, which is the characteristic of the herpes family (1). To 
date, nearly 130 herpesviruses were identified. The genome organization and 
sequence as well as the architecture of the virion determines the membership of the 
Herpesviridae family. The size of the herpesvirions varies from 120 to 300 nm 
depending on the variability of tegument thickness and immune modulation. The 
structural components of the virions comprise the core, the capsid, the tegument and 
the envelope. The capsid measures 100 to 110 nm in diameter with an icosahedral 
symmetry and contains 162 capsomers. It surrounds the core which contains the 
dsDNA in the form of a torus (Figure 1). The envelope is a host-derived lipid 
membrane containing viral glycoproteins with a trilaminar appearance. It contains 
numerous protrusions of spikes made up of glycoproteins. The tegument is the 
structure between capsid and envelope. It consists of structural and transcriptional 
regulatory proteins.  
 
Capsid
Tegument
Core
Envelope
Glycoproteins
 
 
Figure 1: The herpesvirus particle consists of an outer envelope, tegument, capsid and core. 
(http://www.virology.net/Big_Virology/BVDNAherpes.html) 
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Based on their biological properties and genome sequencing the Herpesviridae 
family was classified into three subfamilies (Table 1): Alphaherpesvirinae, 
Betaherpesvirinae, and the Gammaherpesvirinae (1). Alphaherpesvirinae are 
characterized by a variable host range, a relatively short reproductive cycle, the 
efficient destruction of infected cells, rapid spreading in culture and the capacity to 
establish latency primarily but not exclusively in sensory ganglia. Betaherpesvirinae 
are classified based on a restricted host range, a long reproductive cycle and a slow 
progression of infection in culture. Latency is maintained in secretory glands, 
lymphoreticular cells, kidneys, and other tissues. This subfamily is classified into 
three genera, the Cytomegaloviruses, Muromegaloviruses, and Roseoloviruses. The 
Gammaherpesvirinae show a host range restricted to the family or order to which the 
natural host belongs. In vitro they replicate in lymphoblastoid cells. 
Gammaherpesvirinae exhibit specificity for either T or B lymphocytes, and latency is 
maintained in lymphoid tissue. This subfamily is divided into two genera, the 
Lymphocryptoviruses and Rhadinoviruses (2). 
 
Table 1: Members and classification of Human Herpesviruses 
Species Sub-
family 
Site of 
latency 
Pathophysiology 
HHV-1  
Herpes simplex virus-1 
α Neurons Gingivostomatitis, conjunctivitis, 
keratitis, encephalitis 
HHV-2  
Herpes simplex virus-2 
α Neurons Herpes genitalis, Herpes 
neonatorum, a.o. 
HHV-3 / VZV 
Varicella zoster virus 
α Neurons Varicella, Herpes zoster 
HHV-4  
Epstein-Barr virus 
γ B cells Congenital infection, infection in 
immuno-suppressed individuals 
HHV-5  
Cytomegalovirus 
ß Monocytes, 
Lymphocytes  
Roseola infantum 
HHV-6  
Roseolovirus 
ß T cell  no clear evidence for a direct 
involvement of 
HHV-7 in any human disease 
HHV-7  
Roseolovirus 
ß T cell infectious mononucleosis, 
Burkitt’s lymphoma, 
nasopharyngeal carcinoma and 
others 
HHV-8  
Kaposi’s sarcoma-
associated herpesvirus 
γ B cell Kaposi’s sarcoma, primary 
effusion lymphoma (PEL),  
multicentric Castleman’s diseases 
(MCD) 
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2.2 Varicella-zoster virus (VZV) 
2.2.1 Disease association 
Varicella-zoster virus is a dsDNA virus, member of the alphaherpesvirus subfamily 
and the only varicellovirus that can infect humans. It causes a primary disease called 
varicella (chickenpox). Upon reactivation from latency it causes a secondary disease 
called zoster (shingles) (3). Weller and colleagues proved from in vitro studies that 
chickenpox and shingles were both caused by VZV. In the course of infection, VZV 
exhibits cell tropism to three major cell types, peripheral blood mononuclear cells 
(PMBC), skin cells, and sensory nerve ganglions (3). 
 
2.2.2 Varicella (chickenpox) 
The term "chickenpox" might originate from the old English word "gicin" which means 
itching. The other version of chickenpox might be the anglicization of the old French 
word "chiche-pois" for chickpea, due to the similarity in size of seeds to the 
chickenpox lesions (4). In 1767, William Heberden, an English physician was the first 
to differentiate chickenpox from smallpox (5). By isolating virus from cell cultures, 
Thomas H. Weller proved that chickenpox and shingles were both caused by VZV. In 
temperate regions >90% of individuals were infected with VZV by 18 years of age 
whereas in tropical regions less than 60% of adults are immune. Varicella illness 
begins with a rash, low-grade fever, and malaise in young children (Figure 2). In older 
children and adults prodromal symptoms like headache, myalgia, anorexia, nausea 
and vomiting are followed by the eruption of a rash (exanthema). The rash first starts 
on the trunk of the face, develops in crops, and spreads to the skin surface (6,7).  
Complicatians of varicella more often occur in immunocompromised people, pregnant 
women, and also increases with age. The most common complications of varicella 
were secondary bacterial infections with S. aureus, or GroupA Streptococci, which 
cause skin and soft tissue infections, osteomyelitis, septicaemia or toxic shock 
syndrome. Central nervous system complications which precede varicella were 
cerebellar ataxia, encephalitis, aseptic meningitis and transverse myelitis (8). Mostly in 
adults varicella causes pneumonia (only in 30% of patients). 
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Figure 2: Varicella replication between invasion of VZV and clinical signs of varicella 
(9)
. 
 
2.2.2.1 Congenital Varicella 
Transfection of varicella to fetuses causes congenital varicella syndrome (CVS) and 
occurs mostly before week 20 of the gestation period. The risk of CVS is lower 
between 0 to 12 weeks (0.55%) and it is higher between weeks 13 to 20 (1.4%) (10,11). 
It is characterised by scarring skin lesions, hypoplasia, low birth weight, damage to 
the eyes, neurological disorders and retarded psychomotor development (12).  
 
2.2.2.2 Neonatal Varicella 
In 1978, Hubbard for the first time reported on congenital varicella. It can be expected 
if a mother contracts chickenpox during the last 3 weeks of pregnancy (13). If the 
mother develops a varicella rash between 5 days before birth to 2 days after birth 
then the risk for congenital varicella might be 20 to 50% and the mortality rate is 20%. 
The fatality is due to the lack of acquired protective antibodies and insufficient cell-
mediated immunity. Neonatal varicella is not fatal for fetuses exposed between 20 
and 6 days before delivery  (14).  
 
2.2.3 Herpes Zoster (shingles) 
The Herpes zoster (HZ) occurs by reactivation of latent VZV existing in the dorsal 
root ganglia (Figure 2). HZ most frequently occurs in the thoracic or lumbar nerve 
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segments (T3-L2) and the distribution area of the trigeminal nerve (V1-3) (12). The risk 
of HZ increases with advancing age at least partly caused by immunosenescence, 
the gradual deterioration of the immune system due to natural aging and also decline 
of cell mediated immunity. In addition, immunocompromised patients who have 
undergone organ transplantation, chemotherapy for cancer, individuals with HIV / 
AIDS are at greater risk for developing HZ (15).  
In Hope-Simpson’s paper on HZ epidemiology the overall annual incidence of HZ 
was 3.4 per 1000 person / year. It increases with age and the incidence of HZ is 
greater in females compared to males. The incidence of HZ increased from 2.4 per 
1000 persons / year in people of age 40 to 49 years to 5.6 per 1000 persons / year in 
those of age 50 to 59, 6.8 per 1000 persons / year in 60 to 69 year olds, 7.2 per 1000 
persons / year in 70 to 79 year olds and 11.0 per 1000 persons / year in people 
above 80 years of age. The estimation of the current incidence rate of HZ shows that 
approximately 1 million cases of HZ occur every year in the USA (for 300 million 
population), 1.7 million in the European Union (for 460 million population), 100,000 in 
Canada (for 32 million population), 80,000 in Australia and New Zealand (for 24 
million population) (16). 
The clinical manifestation of HZ starts with a prodromal phase. Patients were 
reported with symptoms of headache, radicular pain, malaise, and acute photophobia 
before rash appears. An acute phase follows the prodromal phase characterised by a 
unilateral dermatomal rash not crossing the midline of the body. The rash is followed 
by unbearable itching and allodynia (pain provoked by innocuous stimuli). Some 
patients experience allodynia, pain, itching and burning without rash, the condition is 
known as zoster sine herpete. The rash appears as erythematous and 
maculopapular initially, turns to coalescing clusters of clear vesicles containing high 
concentration of VZV. The rash lasts 7 to 10 days and fully heals within 2 to 4 weeks 
(Figure 3)  (17,18,19). The common complications during HZ are postherpetic neuralgia 
(PHN), zoster ophthalmicus, vasculopathy, myelitis, retinal necrosis, meningitis and 
encephalitis. 
 
2.2.3.1 Postherpetic neuralgia 
PHN occurs in 10 to 20% of HZ patients and the risk of PHN is 50% if the patients 
are above 50 years of age (12). PHN is an intractable pain occurring in a dermatomal 
distribution which can persist for months to several years. It is defined as pain 
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persisting more than 4 to 6 weeks after the rash resolves, and is the most frequent 
neurologic complication of zoster. PHN patients have a central area of cutaneous 
scarring and sensory loss surrounded by an area of hypersensitivity and allodynia. 
Allodynia is present in nearly 70% of PHN patients and patients with allodynia 
experience severe pain after a light, normally innocuous, touch of the affected skin by 
things as trivial as cold wind or a piece of cloth (16,12). Oakleander and Rowbotham 
along with their colleagues have shown a greater loss of small cutaneous nerves 
from the skin biopsy of zoster patients experiencing PHN (20). Neuronal loss, scarring 
in the region of sensory ganglions and the spinal dorsal horn corresponding to the 
area of the affected skin are observed in individuals with prolonged PHN. Many of the 
sensory abnormalities that characterise PHN are due to death of primary neurons 
involved in sensory ganglions and secondary neurons in the corresponding dorsal 
horn of the spinal cord. 
 
 
   a)                                                                                                     b) 
Figure 3: Herpes zoster. a) The classic skin findings of herpes zoster are grouped vesicles on a red 
base in a unilateral, dermatomal distribution. b) The progression of herpes zoster lesions through 
stages, beginning as red macules and papules, finally evolve into vesicles and form pustules and 
crusts. A common site for the distribution of ophthalmic division is the trigeminal nerve ( taken from 
(21)
). 
 
2.2.4 Latency 
After primany infection, VZV becomes latent in the trigeminal and dorsal root ganglia 
(DRG). In 1965, Hope-Simpson originally proposed that during varicella infection a 
viraemia disseminates VZV to the skin. The virus then reaches to sensory nerve 
ganglia and establishes latency which may subsequently reactivate to cause zoster 
(22). Although the molecular mechanism for reactivation from latency is unknown, VZV 
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reactivation can occur spontaneously or by triggering factors like infection, 
immunosuppression, trauma, x-irradiation and malignancy. Reactivation is more 
common in elderly people and immunosuppressed individuals such as those with HIV 
infection (23,22).  
In 1995, Dueland and collegues combined VZV in situ amplification with in situ 
hybridization (ISH) to report the presence of latent VZV DNA exclusively in the 
cytoplasm of neurons in the trigeminal ganglia (TG) (24). By using ISH, Lungu et al. 
were the first to report the presence of latent VZV in both neuronal and non-neuronal 
cells like satellite cells (25). This was further clarified by Kennedy et al. combining 
molecular techniques like PCR, FISH, and in situ DNA amplification by PCR on 30 
human TG. This showed that latent VZV was located predominantly in the nuclei of 2 
to 5% of neurons and less than 0.1% of non-neuronal satellite cells (22). VZV does not 
contain any homologues of the HSV-1 LAT genes. During latency in sensory nerve 
ganglia, VZV gene expression is restricted to expression of a limited number of 
genes. So far transcripts and translates of ORF4, ORF21, ORF29, ORF62, ORF63 
were identified in latently infected human trigeminal ganglia. The proteins of the 
mentioned ORFs were localised in the cytoplasm of latently infected neurons of 
dorsal root ganglia which is contrasting with the localisation of these proteins during 
the lytic cycle. In the presence of ORF62, a transactivator protein, some of the VZV 
latently expressed proteins may restrict regulatory proteins from entering the nucleus 
(26). Although many of these VZV genes were expressed during latency, only 
transcripts mapping to gene 63 were consistently detected in latently infected TG, a 
suggested hallmark of VZV latency (27). 
 
2.2.5 Virus Particle 
The VZV virion is pleomorphic to spherical in shape and measures approximately 
180 to 200 nm in diameter (1). The electron-dense core contains one copy of the 
linear double-stranded DNA genome. The genome of VZV is wound tightly as a toroid 
around a dense protein rod which is similar to that observed in HSV-1. But this has 
been questioned by recent findings since virion particles fixed for electron microscopy 
with non-dehydrating agents show a more loose fibrillar cage of strands surrounding 
a dense cylindrical core of DNA fibres (28). 
The VZV nucleocapsid is indistinguishable in appearance with respect to other 
herpesviruses. Electron microscopy studies revealed that the VZV nucleocapsid 
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contains 162 capsomers arranged like an icosahedron with a 5:3:2 axial symmetry 
and measuring 80 to 120 nm. The pentameric proteins are located at each of the 12 
vertices and hexameric elements comprise its facets (29). The predicted ORFs that 
form the structural components of nucleocapsids are ORFs 20, 23, 33, 33.5, 40, and 
41 which are the orthologues of the HSV-1 capsid proteins VP19C (UL38), VP26 
(UL35), VP24 (UL26), VP22 (UL26.5), VP5 (UL19), and VP23 (UL18), respectively 
(Figure 4). 
The tegument of VZV contains immediate-early proteins like ORF4, 62, 63 and also 
ORFs 10, 47, and 66.  While transported along various membranes, the nucleocapsid 
assembles at host cellular membranes thus modified to display virally encoded 
glycoproteins. Nucleocapsids acquire a primary envelope in patches from nuclear 
membrane, and a secondary one from the Golgi apparatus or other cytoplasmic 
membranes, so most likely no singular source of the VZV envelope exists (30). 
 
  
            a)                                                                        b) 
Figure 4: Varicella zoster virions. a) High resolution image of VZV at 400,000x magnification. The 
VZV envelopes were covered by small protrusions 
(31)
. b) Electronmicrograph of enveloped particle. 
(http://en.wikipedia.org/wiki/File:Varicella_%28Chickenpox%29_Virus_PHIL_1878_lores.jpg) 
 
2.3 Genome Organisation of VZV 
In 1986, Davidson and Scott determined the complete nucleotide sequence of the 
VZV genome (strain Dumas) (32). It is a linear double-standard DNA molecule of 
approximately 125 kbp encoding 71 unique viral proteins. It consists of two coding
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regions: the unique long region (UL, about 105,000 bp) and unique short region (US, 
5,232 bp), both flanked by the internal repeat regions (IRL, IRS) and terminal repeat 
regions (TRL, TRS). Three ORFs (ORF63/70, ORF62/71, ORF64/69) are located 
within the IRS and TRS, and are therefore duplicated within the viral genome (Figure 
5). 
By using electron microscopy the inverted repeat structure of a VZV genome was 
verified. In total, 46% of the VZV genome is composed of Guanine and Cytosine 
(GC). The UL and US regions contain 43 to 44% of GC, whereas the GC content of 
the TRS and IRS regions is 59% and that of the TRL and IRL regions is 68%(1). 
Usually, the VZV genome is present as a linear molecule in virions but in rare cases it 
may also exist as a circular, supercoiled form. The genome of VZV can exist in four 
different isomeric forms while two forms predominate (33). Both ends of the VZV 
genome contain a single unpaired nucleotide, Cytosine (C) at the left end and 
Guanine (G) at the right end. Due to complementarity they make basepairs to form a 
circular molecule (34). The genome consists of five regions with direct sequence 
repeats, termed R1 to R5. Due to the difference in lengths, R1 to R5 is being used to 
distinguish different VZV strains by restriction endonuclease analysis. So, due to the 
variations in number of repeats, the genome size of different VZV strains has 
different lengths (35).  
Though some of the genes have putative polyadenylation signals shortly after the 
end of their ORF, many are arranged in unidirectional families of up to four genes 
with single putative polyadenylation signals at the 3’ end of the family. For 11 VZV 
genes the reading frames overlap. ORF42 and 45 are splice products of the same 
gene and ORFS/L splicing occurs in noncoding regions (36). Most of the VZV genome 
is co-linear with the HSV-1 genome. The comparison of the HSV-1 and VZV 
predicted aminoacid sequences indicates that homologous genes are organised 
similarly in both genomes. In the UL region, 56 out of 62 and in the US region all four 
genes of VZV genes are homologous to the HSV-1 genome (37). Six of the VZV 
genes (ORF1, ORF2, ORF13, ORF32, ORF57, ORFS/L) do not have homologs in 
HSV-1 (36). 
VZV shares 41 conserved genes in comparison with seven other herpesviruses and 
all are located in the UL region of the VZV genome. These conserved genes are 
located within a given block and co-linear between viruses in a given block. The 
genes that are mostly conserved are the IE gene ORF4, viral enzymes, as well as 
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structural proteins (major capsid protein, glycoproteins gB, gH, gL). The three regions 
of the VZV genome  that do not contain ORFs were 3’ to the UL region between 
ORF60 and 61, between ORF62 and 63 and at the origin of replication. The 
phylogenetic tree of known human herpesviruses as well as several other (non-
human) herpesviruses was derived by comparing the aminoacid sequences of the 
major capsid protein gene (38) (Figure 6). 
 
 
Figure 6: Phylogenetic tree of herpesviruses. The phylogenetic tree was constructed by comparing 
the amino acid sequences of the major capsid protein gene. EBV denotes Epstein-Barr virus, EHV-2 
Equine herpesvirus type 2, HVS Herpesvirus saimiri, HSV-1 Herpes simplex virus type 1, HSV-2 
Herpes simplex virus type 2, EHV-1 Equine herpesvirus type 1, PRV Pseudorabies virus, VZV 
Varicella-zoster virus, HCMV Human Cytomegalovirus, HHV-6 Human herpesvirus 6, and HHV-7 
Human herpesvirus 7 (according to 
(38)
). 
 
2.4 Replication cycle of VZV 
VZV attaches to the host cell surface through interactions of the mannose-6-
phosphate (Man-6-P) groups present on gB, gH, gL molecules in the outer envelope 
with heparin sulphate proteoglycans, and also with the insulin-degrading enzyme 
(IDE) through gE. The viral envelope fuses with the host cell plasma membrane to 
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enter the cell (3,39). Then tegument proteins are partially removed from the capsid that 
is transported through the host cell cytosol to the nuclear pore where the viral DNA 
genome is injected into the nucleus (40).  
Following infection into the nucleus, the linear VZV genome circularises controlled by 
several tegument proteins such as ORF4, ORF10, ORF62, ORF63. In the nucleus 
the viral genome is expressed in a cascade manner in three stages, each of which is 
dependent on the host cell RNA polymerase. In the first stage, immediate early (IE) 
genes are expressed, which are proteins involved in transcriptional regulation. Upon 
synthesis in the host cytoplasm the IE proteins enter the nucleus where they further 
downregulate IE gene transcription and initiate synthesis of early (E) proteins. The E 
proteins consist of the DNA helicase / primase complex, the DNA polymerase and 
single stranded DNA binding proteins, together forming the machinery that replicates 
viral DNA. In the third stage of gene expression, late (L) proteins which encode 
structural components like capsomers and glycoproteins are synthesized. VZV DNA 
circularises by ligation of single nucleotide extensions at the 3’ termini of the L and S 
segment. The replication starts after circularisation of the VZV genome. The head to 
tail concatemers that are cleaved into unit-length genomes are packed into newly 
assembled capsids (3).  
The immature nucleocapsids are assembled inside of the host nucleus, packed with 
one viral genome each and equipped with several tegument proteins. Subsequently, 
these nucleocapsids bud through the inner nuclear membrane into the perinuclear 
cisternae thereby acquiring a primary envelope (Figure 7). Upon fusion of the primary 
envelope with the outer nuclear membrane, the naked nucleocapsid is released into 
the cytoplasm (41). 
Secondary envelopment occurs at the trans-Golgi network (TGN). As a prerequisite, 
viral glycoproteins have to be synthesized at the endoplasmic reticulum (ER), 
processed posttranslationally and transported to the site of envelopment (Figure 7). 
The final envelopment and tegumentation of the VZV virions occur at specialised 
TGN cisternae. The glycoproteins with adhered tegument proteins are concentrated 
in the concave membrane wrapping TGN cisternae (3). The viral nucleocapsids 
converge with the glycoproteins and tegument and the TGN sacs wrap around the 
nucleocapsid and fuse, giving rise to mature virions. A range of glycoproteins are 
exposed on the virion surface required for its docking at and fusion with the 
plasmamembrane to enter a new host cell for further amplification. 
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Figure 7: Intracellular transport and maturation of varicella-zoster virus 
(41)
. 
(http://journals.cambridge.org/fulltext_content/ERM/ERM7_15/S146239940500966Xsup009.htm) 
 
2.5 Limitations within the VZV research 
Research on VZV is restricted for several reasons. First, it is impossible to prepare 
reproducible high titers of cell-free virus since VZV is highly cell-associated (42,43). 
Furthermore, VZV exhibits a highly restricted host specificity, so there is no 
appropriate small animal model available. This is in contrast to HSV-1, which has a 
broad host specificity, and is able to replicate within mice. To overcome these 
limitations in the VZV field, new technologies have been developed. For example, a 
chimeric mouse model based on the implantation of small pieces of human fetal 
tissue, e.g. skin, thymus or liver, into SCID mice was developed to analyze the viral 
organotropism in vivo (44). After engraftment the xenografts form a small human 
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“microenvironment” that enables the analysis of viral replication within these different 
human tissues. 
 
2.6 Gateway® Technology 
Recombinatorial cloning (Invitrogen Gateway® system) is a procedure based on the 
bacteriophage lambda site-specific recombination system. This recombination 
mechanism is responsible for the site-specific integration of this phage into the  E.coli 
chromosome (45). The lambda recombination is site-specific and occurs between attB 
sites on the E.coli chromosome and attP sites on the Lambda DNA and gives rise to 
attL and attR sites (46). 
Figure 8 explains the Gateway®  technology. An ORF is first cloned into a so-called 
donor vector (BP-reaction) and in a second, consecutive step into one or several 
different destination vectors (LR-reaction). The BP reaction requires attB sites on the 
gene of interest (in our case a PCR-amplified viral ORF) and attP sites on the donor 
vector. The recombination reaction is catalysed by the BP-clonase enzyme mix. After 
recombination, the resulting vectors comprise the subcloned viral ORF with attL sites. 
The LR reaction requires attL sites on the gene of interest and attR sites on the 
destination vectors. This recombination reaction is catalysed by the LR Clonase 
enzyme mix. After the recombination process, the resulting subcloned viral ORFs are 
flanked by attB sites.  
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Figure 8: Schematic diagram of recombinational cloning (Invitrogen Gateway®) procedure.  
 
2.7 Antibodies 
Antibodies are proteins present on B-cell membranes and secreted by plasma cells 
and able to bind to specific sites of an antigen. In principle, antibodies of the IgG type 
are composed of four peptide chains (Figure 9), two identical heavy (H) chains with a 
molecular weight (MW) of 50,000 and two identical light (L) chains of MW of 25,000 
daltons. Each light chain is joined to a heavy chain by a single intermolecular 
disulfide bond and by non-covalent interactions. Similarly, both heavy chains are 
joined by inter-chain disulphide bonds and noncovalent interactions. Both light and 
heavy chains constitute the antigen-binding site of the antibody molecule. The first 
110 aminoacids of the amino-terminal region of a heavy or light chain possess a high 
degree of variability in aminoacid sequence called V region: VL in light chain and VH 
in heavy chain. The specific nature of an antibody is defined by this V region. Within 
the V regions most of the differences fall into the so-called complementarity-
determining region (CDRs). The regions beyond the variable regions are relatively 
 20 
constant, termed C regions, CL in light chain and CH in heavy chain. Based on 
structural and functional patterns antibodies are classified into five types IgA, IgD, 
IgE, IgG, IgM. Glycosylation in antibodies is restricted to the constant region. 
Chemical and proteolytic cleavage of IgGs provided the first clue of their three-
dimensional structure. Proteolytic cleavage of IgG with papain produces three 
fragments, two of which are identical while the third is different. Due to their activity to 
bind the antigen, two identical fragments are called antigen-binding fragments (Fab). 
The Fab fragments contain both variable and constant regions of heavy and light 
chains. The non-identical fragment designated Fc fragment (fragment crystallizable) 
is composed by the constant regions of two heavy chains (47). 
 
 
 
a)                                                                        b)  
Figure 9: Graphical depiction of immunoglobulins. a) Schematic diagram of immunoglobulin 
structure derived from amino acid sequencing studies. H, heavy chain; L, light chain; V, variable 
region; C, constant region; CHO, carbohydrate attachment site; S-S, disulfide bond; Fab, antigen-
binding fragment; Fc, crystallizable fragment. b) Ribbon presentation of an intact monoclonal antibody 
(47)
. 
http://www.abcam.com/index.html?pageconfig=resource&rid=11258&pid=11287 
http://en.wikipedia.org/wiki/Antibody 
 
2.8 Aim of the PhD thesis 
VZV is a neurotropic alphaherpesvirus that contains a 125 kb dsDNA genome 
encoding 70 viral proteins. Research on VZV is restricted due to various reasons, like 
difficulty in isolating virus from cells, or lack of animal model. Because of this very 
little is known about its morphogenesis, replication, reactivation from latency and the 
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functional and biochemical characteristics of many VZV specific genes were not 
studied so far.  
 
 
 
Figure 10: Schematic diagram depicting the pipeline for high-throughput antibody screening. 
 
The aims of this study and the experimental approach of which is schematically 
depicted in Figure 10 were (i) to construct a VZV ORFeome by recombinational 
cloning, (ii) to construct expression libraries by subcloning a VZV ORFeome library 
into pET derived expression vectors containing four different tags like N-His6, C-His6, 
N-MBP, and N-GST, (iii) to express and purify all VZV encoded proteins and 
immunize them to mice, (iv) to screen hybridoma clones for secretion of VZV-specific 
antibodies using ELISA, Western Blotting and indirect immunofluorescence analysis, 
(v) to study the localization of the VZV proteome in the viral context. 
Tag
purified 
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VZV Protein
Expression of tagged 
proteins in E.coli
Purification of 
tagged proteins
on Ni-NTA
total lysate
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E.coli carrying 
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1. Screening for monoclonal antibodies 
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3. Materials and Methods 
 
3.1 Materials 
3.1.1 Equipment 
Bacterial Shaker     Kühner, Bürsfelden, Switzerland 
Balances      Sartorius, Göttingen, Germany 
Centrifuge GP     Beckman, Palo Alto, USA 
Centrifuge J2-21     Beckman, Palo Alto, USA 
Centrifuge Varifuge 3.0R    Heraeus, Hanau, Germany 
Centrifuge Minifuge RF    Heraeus, Hanau, Germany 
Centrifuge Labofuge T    Heraeus, Hanau, Germany 
Centrifuge, refrigerated / non-refrigerated Heraeus, Hanau, Germany 
Confocal microsope  Leica, Mannheim, Germany 
Film Developing Machine Optimax Typ TR MS Laborgeräte, 
Heidelberg, Germany 
Fluorescence Microscope    Leica, Mannheim, Germany 
Fridge (4°C)      Liebherr, Ochsenhausen, Germany 
Freezer (-20°C)     Liebherr, Ochsenhausen, Germany 
Freezer (-80°C) Forma Scientific, Inc., Marietta, Ohio, 
USA 
Cryo 1°C Freezing Container   Nalgene Nunc, Wiesbaden, Germany 
Gel Dryer      Bio-Rad, Munich, Germany 
GelAir Drying System    Bio-Rad, Munich, Germany 
Incubators for Cell Culture (37°C) Forma Scientific, Inc., Marietta, Ohio, 
USA 
Laminar Flow Hood Steril Gard II A/B3 The Baker Company, Sanford, Maine, 
USA  
Magnetic Stirrer with heating block  Janke & Kunkel, Staufen, Germany 
Microwave      AEG, Berlin, Germany 
PCR Thermal Cycler GeneAmp 2400  Perkin Elmer, Weiterstadt, Germany 
pH-Meter      WTW, Weilheim, Germany 
Pipettes      Gilson, Villies Le Bel, France; 
Eppendorf, Hamburg, Germany 
Pipetting Aid      Technomara, Zürich, Switzerland 
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Electrophoresis Power supply EPS200 Amersham-Pharmacia, Freiburg, 
Germany 
Overhead Mixer     Heidolph, Schwabach, Germany 
384-Pin Replicator     Nalge Nunc International 
Sonifier 450  Branson Ultrasonics Corp., Danbury, 
USA 
Thermomixer     Eppendorf, Hamburg, Germany 
UV-Transilluminator (366 nm)   Vetter, Wiesloch, Germany 
   (254 nm)   Konrad Benda, Wiesloch, Germany 
Vortex Mixer      IKA Works, Inc, Wirmington, USA 
Water Bath      Julabo, Seelbach, Germany 
       GFL, Burgwedel, Germany 
 
3.1.2 Chemicals 
Acetic Acid      Roth, Karlsruhe, Germany 
Acrylamide/Bisacrylamide 37,5/1   Roth, Karlsruhe, Germany 
(Rotiphorese Gel 30)  
Agar for plates     Gibco BRL, Karlsruhe, Germany 
Agarose Electrophoresis Grade   Invitrogen, Karlsruhe, Germany 
Ammonium Persulfate (APS)   Sigma, Munich, Germany 
Ampicillin  Roche Diagnostics, Mannheim, 
Germany 
Bacto Peptone     BD Biosciences Clontech, Heidelberg, 
Germany 
Bacto Tryptone     BD Biosciences Clontech, Heidelberg, 
Germany 
Bacto Yeast Extract  BD Biosciences Clontech, Heidelberg, 
Germany 
Bromophenol Blue     Serva, Heidelberg, Germany 
BSA (Bovine Serum Albumin)   Sigma, Munich, Germany 
Calcium Chloride     Merck, Darmstadt, Germany 
Chloramphenicol     Sigma, Munich, Germany 
Coomassie Brilliant Blue R-250   Bio-Rad, Munich, Germany 
Dextrose      BD Biosciences Clontech, Heidelberg, 
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Germany 
Dimethylsulfoxid (DMSO)    Merck, Darmstadt, Germany 
Dithiothreitol (DTT)     Roth, Karlsruhe, Germany 
dNTPs RocheDiagnostics,Mannheim, 
Germany 
Dulbecco’s modified Eagle’s medium (DMEM) Gibco BRL, Karlsruhe, Germany 
Ethanol (EtOH)     Riedel-de Haën, Seelze, Germany 
Ethidium Bromide     Sigma, Munich, Germany 
Ethylendiamintetraacetate Disodium Salt Roth, Karlsruhe, Germany (EDTA) 
Ethylene Glycol     Sigma, Munich, Germany 
Fetal Calf Serum (FCS)    Gibco BRL, Karlsruhe, Germany 
Gentamycin      Serva, Heidelberg, Germany 
Glucose      Merck, Darmstadt, Germany 
Glycerol      Roth, Karlsruhe, Germany 
Glycine      Serva, Heidelberg, Germany 
Hydrochloric Acid (HCl)    Merck, Darmstadt, Germany 
Imidazole      Fluka, Seelze, Germany 
Isopropanol      Riedel-de Haën, Seelze, Germany 
Isopropylthio-b-D-galactosid (IPTG)   Roth, Karlsruhe, Germany 
Kanamycin      Serva, Heidelberg, Germany 
Magnesium Chloride     Merck, Darmstadt, Germany 
Magnesium Sulfate     Merck, Darmstadt, Germany 
2-Mercaptoethanol      Merck, Darmstadt, Germany 
Methanol      Merck, Darmstadt, Germany 
Polyethylene Glycol (PEG 1000)   Sigma, Munich, Germany 
Phosphate Buffered Saline (PBS) Dulbecco’s Gibco BRL, Karlsruhe, 
Germany 
Ponceau S      Sigma, Munich, Germany 
Potassium Acetate     Riedel-de Haën, Seelze, Germany 
Potassium Chloride     Merck, Darmstadt, Germany 
Potassium Phosphate Salts   Merck, Darmstadt, Germany 
Protein G Sepharose Fast Flow Amersham-Pharmacia, Freiburg, 
Germany 
RPMI (Rosswell Park Memorial Institute) 1640 Gibco BRL, Karlsruhe, Germany 
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Skim Milk Powder     Merck, Darmstadt, Germany 
Sodium Acetate     Riedel-de Haën, Seelze, Germany 
Sodium Azide     Serva, Heidelberg, Germany 
Sodium Chloride     Riedel-de Haën, Seelze, Germany 
Sodium Carbonate     Merck, Darmstadt, Germany 
Sodium Hydroxid     J.T.Baker B.V., Deventer, Holland 
Sodium Phospate salts    Merck, Darmstadt, Germany 
Tetramethylethylendiamin (TEMED) Amersham-Pharmacia, Freiburg, 
Germany 
Tris (hydroxymethyl) aminomethan (Tris) Roth, Karlsruhe, Germany 
Triton X-100      Serva, Heidelberg, Germany 
Trypsin      Gibco BRL, Karlsruhe, Germany 
Tween 20      Merck, Darmstadt, Germany 
Urea       Roth, Karlsruhe, Germany 
 
3.1.3 Additional materials 
Autoradiography Films BIOMAX-MR  Eastman-Kodak, Rochester, USA 
Cell Culture Plastic Ware    Greiner, Nürtingen, Germany 
Nunc, Wiesbaden, Germany 
Falcon/Becton Dickinson, Heidelberg, 
Germany 
Filter Paper (3 mm)     Whatman Ltd., Maidstone, England 
Glass Slides for IF Marienfeld, Bad Mergentheim,  
Germany 
Protran Nitrocellulose Transfer Membranes Schleicher & Schuell, Dassel, 
Germany 
Sterile Filter Units     Millipore 
Single-well Microtiter Plates   Omnitray; Nalge Nunc International 
 
3.1.4 Cell lines 
HEK 293   human embryonal kidney cell line (ATCC: CRL-1573) 
MeWo   human melanoma cell line ((ATCC: HTB-65) 
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3.1.5 Bacterial strains 
DH5α    Invitrogen, Karlsruhe, Germany 
Genotype: 
F− 80dlacZΔM15 endA1 recA1 hsdR17 (rk
− mk
+) supE44 
thi-1 λ− gyrA96 relA1 Δ (lacIZYA-argF)U169  
     
DB3.1    Invitrogen, Karlsruhe, Germany  
Genotype: 
F−gyrA462 endA (sr1-recA) mcrB mrr hsdS20 (r B - m B - ) 
supE44 ara14 galK2 lacY1 proA2 rpsL20(Str R ) xyl5 
ë - leu mtl1 
  
DH10B   Invitrogen, Karlsruhe, Germany 
Genotype: 
F−mcrA Δ(mrr-hsdRMS-mcrBC) 80dlacZΔM15 ΔlacX74 
deoR recA1 araD139 Δ(ara leu)7697 galU galK rpsL 
endA1 nupG 
 
3.1.6 Plasmids  
pDONR207 (Gmr)  Invitrogen, Karlsruhe, Germany 
pETG based vectors N-His, C-His, N-GST, N-MBP.  
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Figure 11:  The pDONR207 vector contains attP sites at both sides of the ccdB cassette. 
 
3.1.7  Oligonucleotides 
 
Table 2: Forward Primers 
ORF No. Forward Primer 
ORF1 for AAAAAGCAGGCTCCGCCatgTCCAGGGTATCGGAGTATGG 
ORF2 for AAAAAGCAGGCTCCGCCatgCATGTAATTTCTGAGACACTTGC 
ORF3 for AAAAAGCAGGCTCCGCCatgGATACAACGGGAGCTTCCGAAAG 
ORF4 for AAAAAGCAGGCTCCGCCatgGCCTCTGCTTCAATTCCAACC 
ORF5 for AAAAAGCAGGCTCCGCCatgCAGGCTTTAGGAATCAAGACAGAAC 
ORF5F for AAAAAGCAGGCTCCGCCatgTATTTACAATTTCGACGAATACGTCG 
ORF6 for AAAAAGCAGGCTCCGCCatgGATAAATCCTCCAAACCGACGATTCG 
ORF7 for AAAAAGCAGGCTCCGCCatgCAGACGGTGTGTGCCAGCTTATGTG 
ORF8 for AAAAAGCAGGCTCCGCCatgAACGAAGCGGTAATTGATCCCATCTTG 
ORF9 for AAAAAGCAGGCTCCGCCatgGCATCTTCCGACGGTGACAGACTTTG 
ORF9a for AAAAAGCAGGCTCCGCCatgGGATCAATTACCGCTTCGTTCATATTAATAAC 
ORF10 for AAAAAGCAGGCTCCGCCatgGAGTGTAATTTAGGAACCGAACATCCTAG 
ORF11 for AAAAAGCAGGCTCCGCCatgCAGTCGGGTCATTATAACCGGAGGC 
ORF12 for AAAAAGCAGGCTCCGCCatgTTTTCTCGGTTTGCGCGTTCCTTTTCCAGCG 
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ORF No. Forward Primer 
ORF13 for AAAAAGCAGGCTCCGCCatgGGAGACTTGTCATGTTGGACAAAGGTGC 
ORF14/14N for AAAAAGCAGGCTCCGCCatgAAGCGGATACAAATAAATTTAATTTTAACGATCG 
ORF15 for AAAAAGCAGGCTCCGCCatgGCCGTGAATGGTGAAAGAGCTGTCCATG 
ORF15F for AAAAAGCAGGCTCCGCCatgGTCGATGCCGCCACCGATTTGCAAGATACG 
ORF16 for AAAAAGCAGGCTCCGCCatgGATTTGAGGTCGCGTACAGACGATGCTTTGG 
ORF17 for AAAAAGCAGGCTCCGCCatgGGGCTCTTTGGACTGACACGCTTTATCC 
ORF18 for AAAAAGCAGGCTCCGCCatgGATCAGAAAGATTGCAGTCATTTTTTTTACAGGC 
ORF19 for AAAAAGCAGGCTCCGCCatgGAGTTCAAAAGAATTTTTAATACGGTTCATGAC 
ORF20 for AAAAAGCAGGCTCCGCCatgGGGAGTCAACCAACCAACTCGCATTTTAC 
ORF21 for AAAAAGCAGGCTCCGCCatgGAAGAACCAATTTGTTATGATACAC 
ORF22N for AAAAAGCAGGCTCCGCCatgGATATAATTCCGCCTATAGCTGTCACTGTTGC 
ORF22C for AAAAAGCAGGCTCCGCCatgATATTACGAACCTCGGGGGATCTATTAC 
ORF23 for AAAAAGCAGGCTCCGCCatgACACAACCCGCATCGTCTCGTGTAGTC 
ORF24/24N for AAAAAGCAGGCTCCGCCatgTCACGGAGAACGTATGTACGGAGTGAAC 
ORF25 for AAAAAGCAGGCTCCGCCatgTACGAATCGGAAAATGCGTCGGAAC 
ORF26 for AAAAAGCAGGCTCCGCCatgGATCGGGTAGAATCAGAAGAACCCATGG 
ORF27 for AAAAAGCAGGCTCCGCCatgCATTTAAAGCCTACCAGATTTTTCCACGC 
ORF28 for AAAAAGCAGGCTCCGCCatgGCGATCAGAACGGGGTTTTGTAATCCC 
ORF29 for AAAAAGCAGGCTCCGCCatgGAAAATACTCAGAAGACTGTGACAGTGC 
ORF30 for AAAAAGCAGGCTCCGCCatgGAATTGGATATTAATCGAACATTGTTGG 
ORF31/31N for AAAAAGCAGGCTCCGCCatgTTTGTTACGGCGGTTGTGTCGGTCTCTCC 
ORF31C for AAAAAGCAGGCTCCGCCatgCTTAAAACAAGCCCGATGAAGGC 
ORF32 for AAAAAGCAGGCTCCGCCatgGAATCGTCTAACATTAACGCGCTAC 
ORF33 for AAAAAGCAGGCTCCGCCatgGCTGCTGAAGCTGACGAAGAGAAC 
ORF34 for AAAAAGCAGGCTCCGCCatgACGGCGAGATATGGGTTCGGATC 
ORF35 for AAAAAGCAGGCTCCGCCatgTCCGCTAGTCGAATTCGGGCCAAG 
ORF36 for AAAAAGCAGGCTCCGCCatgTCAACGGATAAAACCGATGTAAAAATGGGCG 
ORF37/37N for AAAAAGCAGGCTCCGCCatgTTTGCGCTAGTTTTAGCGGTGGTAATTCTTCC 
ORF38 for AAAAAGCAGGCTCCGCCatgGAATTTCCATATCATTCAACCGTATCTTATAAC 
ORF39/39N for AAAAAGCAGGCTCCGCCatgAACCCACCCCAAGCCCGCG 
ORF40 for AAAAAGCAGGCTCCGCCatgACAACGGTTTCATGTCCCGCTAAC 
ORF41 for AAAAAGCAGGCTCCGCCatgGCTATGCCATTTGAGATAGAGGTATTG 
ORF42 for AAAAAGCAGGCTCCGCCatgCCGCGTGTTTTAGCACATAGCG 
ORF43 for AAAAAGCAGGCTCCGCCatgGAAGCCCATTTGGCAAATGAAACCAAAC 
ORF44 for AAAAAGCAGGCTCCGCCatgGAATTACAACGCATATTTCCGCTGTACACCG 
ORF45 for AAAAAGCAGGCTCCGCCatgTCATTGATAATGTTTGGTCGTACGCTTGGTG 
ORF46 for AAAAAGCAGGCTCCGCCatgTCAGGCCACACTCCAACCTAC 
ORF47 for AAAAAGCAGGCTCCGCCatgGATGCTGACGACACACCCCCC 
ORF48 for AAAAAGCAGGCTCCGCCatgGCACGATCGGGATTGGATAGG 
ORF49 for AAAAAGCAGGCTCCGCCatgGGACAATCTTCATCCAGCGGTC 
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ORF No. Forward Primer 
ORF50 for AAAAAGCAGGCTCCGCCatgGGAACTCAAAAGAAGGGGCCGC 
ORF50C for AAAAAGCAGGCTCCGCCatgCGTGCATATGTGTATCATCGACAGAAACGC 
ORF51 for AAAAAGCAGGCTCCGCCatgTCTCCCAACACCGGGGAGAG 
ORF52 for AAAAAGCAGGCTCCGCCatgGACGCAACGCAGATTACCTTGGTTAG 
ORF53 for AAAAAGCAGGCTCCGCCatgCAGCGGATTCGACCTTACTGG 
ORF54 for AAAAAGCAGGCTCCGCCatgGCCGAAATAACGTCTCTTTTTAATAACAGTTCC 
ORF55 for AAAAAGCAGGCTCCGCCatgAAAAGATCAATTTCTGTAGACAGTTCTTCACCC 
ORF56 for AAAAAGCAGGCTCCGCCatgAAAAATCCGCAGAAATTAGCGATCACATTCTTG 
ORF57 for AAAAAGCAGGCTCCGCCatgGACGTACGAGAACGTAATGTGTTTGG 
ORF58 for AAAAAGCAGGCTCCGCCatgTTTTCGGAGTTGCCTCCTTCCGTACC 
ORF59 for AAAAAGCAGGCTCCGCCatgGATGTGTCTGGGGAGCCGACCG 
ORF60 for AAAAAGCAGGCTCCGCCatgGCATCACATAAATGGTTACTGCAG 
ORF60C for AAAAAGCAGGCTCCGCCatgCCGCTATCGGATGTGAGTTTG 
ORF61 for AAAAAGCAGGCTCCGCCatgGATACCATATTAGCGGGCGGTAG 
ORF62(71) for AAAAAGCAGGCTCCGCCatgGATACGCCGCCGATGCAGCGCTC 
ORF63(70) for AAAAAGCAGGCTCCGCCatgTTTTGCACCTCACCGGCTACGCG 
ORF64(69) for AAAAAGCAGGCTCCGCCatgAATCTCTGCGGATCCCGCGGTG 
ORF65 for AAAAAGCAGGCTCCGCCatgGCCGGACAAAACACCATGGAGG 
ORF66 for AAAAAGCAGGCTCCGCCatgAACGACGTTGATGCAACAGACACC 
ORF67/67N for AAAAAGCAGGCTCCGCCatgTTTTTAATCCAATGTTTGATATCGGCCG 
ORF68 for AAAAAGCAGGCTCCGCCatgGGGACAGTTAATAAACCTGTGGTGGGGG 
ORF68F for AAAAAGCAGGCTCCGCCatgACGAATCCGGTCAGAGCATCCGTC 
 
Table 3: Reverse Primers 
ORF No Reverse primers 
ORF1   rev w/o stop AGAAAGCTGGGTC TTCTCGCTTGCAGCTTGTCG 
ORF1N  rev w/o stop AGAAAGCTGGGTC CCTGTCCATTTGCATTTTCA 
ORF2   rev w/o stop AGAAAGCTGGGTC CATCAATACGCCCTCCGTAG 
ORF3   rev w/o stop AGAAAGCTGGGTC TAGTCCGCCGACAGCCGCTC 
ORF4   rev w/o stop AGAAAGCTGGGTC GCAGTTAAAGGTACTACACT 
ORF5   rev w/o stop AGAAAGCTGGGTC ATGCTTCTGGGAGTTTTCAC 
ORF5F rev w/o stop AGAAAGCTGGGTC CATCAATAACGTAACACCTT 
ORF6   rev w/o stop AGAAAGCTGGGTC ACTCGAAGTTAAATTTGGAT 
ORF7   rev w/o stop AGAAAGCTGGGTC TACAAGCATAACATGGGATT 
ORF8   rev w/o stop AGAAAGCTGGGTC ATGTTTTAGTAGAAAATCGA 
ORF9a  rev w/o stop AGAAAGCTGGGTC CCACGTGCTGCGTAATACAG 
ORF9aN rev w/o stop AGAAAGCTGGGTC AAGGGTGGTGATCATTGATC 
ORF9   rev w/o stop AGAAAGCTGGGTC TTTTCGCGTATCAGTTCTTG 
ORF10  rev w/o stop AGAAAGCTGGGTC ACGCGTTAAAAACCCACACG 
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ORF No Reverse primers 
ORF11  rev w/o stop AGAAAGCTGGGTC ATATTTTCGTAGTAAATGCA 
ORF12  rev w/o stop AGAAAGCTGGGTC ATGATGACTCTTAGGCGTAT 
ORF12N rev w/o stop AGAAAGCTGGGTC TGAGACCGCAGGACCCGTTT 
ORF13  rev w/o stop AGAAAGCTGGGTC AAGAGCCATTTCCATTTTTA 
ORF14  rev w/o stop AGAAAGCTGGGTC TGAACAGCAACGGATGCATAA 
ORF14N rev w/o stop AGAAAGCTGGGTC GTAGGTAGATGCATCGTAGG 
ORF15  rev w/o stop AGAAAGCTGGGTC CGATACATATGTACCACATA 
ORF15N rev w/o stop AGAAAGCTGGGTC CCGCGATGCTGAGGTTATTG 
ORF15F rev w/o stop AGAAAGCTGGGTC ACGAATTCCTTTAAACACGC 
ORF16  rev w/o stop AGAAAGCTGGGTC TTTAACTGTACATATTACGT 
ORF17  rev w/o stop AGAAAGCTGGGTC ATTCCAATATTTTGTTAATA 
ORF18  rev w/o stop AGAAAGCTGGGTC TAAATCGTTTATCACTGTGC 
ORF18N rev w/o stop AGAAAGCTGGGTC TTCTGCAACGGATGGGTTGT 
ORF19  rev w/o stop AGAAAGCTGGGTC TAAAGCACAACTGGTACAGG 
ORF20  rev w/o stop AGAAAGCTGGGTC ATAATAACATTCGTTCCATG 
ORF21  rev w/o stop AGAAAGCTGGGTC AGGGTCACTCCCACTTGTAT 
ORF22  rev w/o stop AGAAAGCTGGGTC TATATATGTTCCATCTAATA 
ORF22N rev w/o stop AGAAAGCTGGGTC ATCTCGGTAGTTAGGTATTC 
ORF23  rev w/o stop AGAAAGCTGGGTC CACCCTACGACTTCTTGAAG 
ORF24   rev w/o stop AGAAAGCTGGGTC TTTCCAGAAAAGCACCGCCC 
ORF24N rev w/o stop AGAAAGCTGGGTC TACGGGTAGAGCAAGTTTCC 
ORF25   rev w/o stop AGAAAGCTGGGTC AGCATCCTTCAATATTTCAT 
ORF26   rev w/o stop AGAAAGCTGGGTC GACATACTTCGATAGGGTGT 
ORF27   rev w/o stop AGAAAGCTGGGTC CCGAGGAGGAACAAAGTCAT 
ORF28   rev w/o stop AGAAAGCTGGGTC ACTTTGATGGAGAATTGCTT 
ORF29   rev w/o stop AGAAAGCTGGGTC AATCATTTCCATTGTAATGT 
ORF30   rev w/o stop AGAAAGCTGGGTC TGAAAACGCCGGGTCCGTTG 
ORF31   rev w/o stop AGAAAGCTGGGTC CACCCCCGTTACATTCTCGG 
ORF31N rev w/o stop AGAAAGCTGGGTC AAACGTGGTAAATCCGTGTA 
ORF32   rev w/o stop AGAAAGCTGGGTC ATCGGTGTCAGAATCTTCAT 
ORF33   rev w/o stop AGAAAGCTGGGTC ACACCGCCCCACCATCATCT 
ORF34   rev w/o stop AGAAAGCTGGGTC CGGTGTGGAGGCAAACTGAG 
ORF35   rev w/o stop AGAAAGCTGGGTC CCCATGGGAAAACATCCCGG 
ORF36   rev w/o stop AGAAAGCTGGGTC GGAAGTGTTGTCCTGAACGG 
ORF37   rev w/o stop AGAAAGCTGGGTC TGTCAGAGGTATTTTATTAT 
ORF37N rev w/o stop AGAAAGCTGGGTC CATTCGTATGGCTTGTCGTC 
ORF38   rev w/o stop AGAAAGCTGGGTC CCTTTGGGTTTTTTTCCCGT 
ORF39   rev w/o stop AGAAAGCTGGGTC AAACGAAATAGATGTTTTTA 
ORF39N rev w/o stop AGAAAGCTGGGTC ATAAAACACGGAGTGTTGCG 
ORF40   rev w/o stop AGAAAGCTGGGTC CGCGGAAGAGGAAGACATC 
 31 
ORF No Reverse primers 
ORF41   rev w/o stop AGAAAGCTGGGTC CACTTGAATCACGGCCGTGC 
ORF42   rev w/o stop AGAAAGCTGGGTC TTTAATAGGCATAAACACGG 
ORF43   rev w/o stop AGAAAGCTGGGTC TTTATGGGGGTTGGGAATAG 
ORF44   rev w/o stop AGAAAGCTGGGTC GGTGGTTGTAGGTTCCGGTT 
ORF45   rev w/o stop AGAAAGCTGGGTC TAAAACACTCACGTTTGTGT 
ORF46   rev w/o stop AGAAAGCTGGGTC CACATCCGTGTGTGGGGTTG 
ORF47   rev w/o stop AGAAAGCTGGGTC TGTCGATCCTATCCAATCCC 
ORF48   rev w/o stop AGAAAGCTGGGTC AAGCAACGGTTTCTCCGTTG 
ORF49   rev w/o stop AGAAAGCTGGGTC ACATTTTGCGCATTTGGAAT 
ORF50   rev w/o stop AGAAAGCTGGGTC CTCCCACCCACTGTTTGATC 
ORF51   rev w/o stop AGAAAGCTGGGTC TAAACTTTCAAAATTTACCG 
ORF52   rev w/o stop AGAAAGCTGGGTC TAAAAACAAGAAGTTATATG 
ORF53   rev w/o stop AGAAAGCTGGGTC CTTTACAACCCGTGGTGAAT 
ORF54   rev w/o stop AGAAAGCTGGGTC AGATCTTCGATCACGTCGCT 
ORF55   rev w/o stop AGAAAGCTGGGTC ATACACAACGTGTACGTTGG 
ORF56   rev w/o stop AGAAAGCTGGGTC CGCGTTTGCGGCGTCCCGTA 
ORF57   rev w/o stop AGAAAGCTGGGTC ACGTTGATGAGCCTTGCAGG 
ORF58   rev w/o stop AGAAAGCTGGGTC CGTTCTCGTACGTCCATGAC 
ORF59   rev w/o stop AGAAAGCTGGGTC TATAACACTCCAATCGATCT 
ORF60   rev w/o stop AGAAAGCTGGGTC TTGGCATACGCGTTGGAACA 
ORF61   rev w/o stop AGAAAGCTGGGTC GGACTTCTTCATCTTGTTTG 
ORF62   rev w/o stop AGAAAGCTGGGTC CCCCCGACTCTGCGGGGGGC 
ORF63   rev w/o stop AGAAAGCTGGGTC CACGCCATGGGGGGGCGGTA 
ORF64   rev w/o stop AGAAAGCTGGGTC GGATCTCTCGTAGGTTCTTG 
ORF65   rev w/o stop AGAAAGCTGGGTC TCCAACAAATTGTGACGTTA 
ORF65N rev w/o stop AGAAAGCTGGGTC TTTTTTACGATGATATATTT 
ORF66   rev w/o stop AGAAAGCTGGGTC ATCTCCAACTTCCATTGGAT 
ORF67   rev w/o stop AGAAAGCTGGGTC TTTAACAAACGGGTTTACAA 
ORF67N rev w/o stop AGAAAGCTGGGTC ATTTTCTGGAGGATCATTAA 
ORF68   rev w/o stop AGAAAGCTGGGTC CCGGGTCTTATCTATATACA 
ORF68F  rev w/o stop AGAAAGCTGGGTC TCGTAGAAGTGGTGACGTTC 
ORFS/L  rev w/o stop AGAAAGCTGGGTC TGTAGTTGAGTTGGGAGGTT 
 
All oligonucleotides were obtained from Invitrogen, Karlsruhe, Germany. 
 
3.1.8 Molecular weight markers 
Gene Ruler 100 bp DNA ladder MBI Fermentas, St.Leon-Rot, Germany 
Gene Ruler DNA 1 kb ladder MBI Fermentas, St. Leon-Rot, Germany 
See Blue Plus 2 Prestained Protein  Invitrogen, Karlsruhe, Germany 
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3.1.9 Kits 
PCR DNA Gel Purification Amersham-Pharmacia, Freiburg, Germany 
Qiafilter Plasmid Maxi Kit Qiagen, Hilden, Germany 
Qiagen Plasmid Mini Kit Qiagen, Hilden, Germany 
 
3.1.10 Secondary antibodies 
Alexa 488     Invitrogen, Karlsruhe, Germany 
Peroxidase-conjugated    Invitrogen, Karlsruhe, Germany 
goat anti-Mouse IgG 
Alkaline-phosphatase-conjugated  Invitrogen, Karlsruhe, Germany 
goat anti-Mouse IgG 
 
3.1.11 Enzymes 
BP Clonase     Invitrogen, Karlsruhe, Germany 
BanII      New England Biolabs, USA 
EcoR1     New England Biolabs, USA 
HindIII     New England Biolabs, USA 
LR Clonase     Invitrogen, Karlsruhe, Germany 
T4 DNA Polymerase   New England Biolabs, USA 
XbaI      New England Biolabs, USA 
 
3.1.12 Viral Stains 
VZV-pOKA     Takahashi et al 1974 (48) 
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3.2 Methods 
 
3.2.1  Bacterial cultures 
3.2.1.1 Cultivating Bacteria 
E. coli bacteria were grown in LB medium or on LB agar plates with specific selective 
antibiotics. Incubation was performed at 37°C with constant shaking. 
 
LB Medium (1l) 
Bacto Tryptone 10 g 
Bacto Yeast Extract   5 g 
NaCl    5 g 
 
LB Agar (1l) 
Agar 15 g 
Bacto Tryptone 10 g 
Bacto Yeast Extract   5 g 
NaCl   5 g 
 
LB Medium for selection: containing either 100 µg/ml Ampicillin, 34 µg/ml 
Chloramphenicol, 15 µg/ml Gentamycin, or 50 µg/ml Kanamycin. 
 
3.2.1.2 Preparation of electrocompetent E. coli DH10 B cells 
The day before the experiment, a preculture of E. coli DH10B was inoculated in 2YT-
medium. The next day, 10ml of the preculture was transferred to a flask containing 1 
litre of 2YT medium and grown at 37°C to obtain an OD600 of 0.6. The cells were 
incubated for 20 min on ice and then centrifuged for 10 min at 4000 rpm at 4°C. Note: 
all further steps were performed on ice or in pre-cooled centrifuges (4°C). The 
resulting bacterial pellet was resuspended in 250 ml ice-cold water and centrifuged 
for 10 min at 4000 rpm. This washing step was repeated two more times with ice-cold 
water and two more times in 150 ml of ice-cold 10% glycerol. After the final washing 
step, cells were resuspended in 5 ml 10% glycerol, aliquoted, shock-frozen in liquid 
nitrogen, and stored at –80°C. 
2YT Medium (1l) 
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Bacto Tryptone 16 g 
Bacto Yeast Extract 10 g 
NaCl   5 g 
 
3.2.1.3 Preparation of chemically competent E. coli DH5α cells 
For preparation of chemically competent cells, a pre-culture of E.coli DH5α was 
grown overnight in 50 ml of 2YT medium. To 1 litre of 2YT medium, 20 ml of 
preculture was added and incubated at 37°C until an OD600 of 0.6 was reached. At 
that point the culture was rapidly chilled on ice for 20 min. From here, all further steps 
were performed on ice and also in pre-cooled centrifuges (4°C). The bacterial culture 
was centrifuged at 4000 rpm for 10 min and the pellet was resuspended in 40ml (1/25 
volume of culture) of icecold TFB I buffer. After 15min incubation on ice, the 
resuspended bacterial culture was centrifuged at 4000 rpm for 10min. The 
supernatant was discarded and the pellet was resuspended in 10 ml of icecold TFB II 
buffer. Finally, aliquots of 200 µl were made, shock-frozen in liquid nitrogen, and 
stored at –80°C. 
 
TFB I (200ml) 
30mM KAc 0.59 g 
50mM MnCl2 1.98 g 
100 mM RbCl 2.42 g 
10mM CaCl2 0.29 g 
15% (v/v) Glycerol 30 ml 
 
TFB II (200ml) 
10 mM MOPS pH 7.0 0.46 g 
75 mM CaCl2 2.21 g 
10mM RbCl 0.24 g 
15% (v/v) Glycerol 30 ml 
Both buffers were sterilized by filtration (Ø0.2 µm) and stored at 4°C. 
 
3.2.1.4 Bacterial transformation 
To transform entry vectors into electrocompetent bacteria DH10B were made 
electrocompetent. About 2 µl of the BP reaction was transformed into 50 µl of 
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eletrocompetent DH10B cells. The parameters for electroporation were 2500 V, 25 
µF, 200 . After electroporation 500µl of SOC medium was added to the cells and 
incubated in the shaker at 900 rpm for 2 hours at 37°C. After this incubation, the 
transformed cells were plated on LB media containing Gentamycin (15 µg/ml) to 
select for pDONR207 and incubated over night at 42°. 
Destination vectors were transformed into chemically competent bacteria. About 2 µl 
of the LR reaction was transformed into 50 µl of DH5α cells by heat shock. 500µl of 
SOC medium was added to the cells and incubated in the shaker at 900 rpm for 2 
hours at 37°C. After this incubation, the transformed cells were plated on LB media 
containing the respective antibiotic: Ampicillin (100 µg/ml) for pHis tag, Kanamycin 
(50 µg/ml) for pMBP tag, and incubated over night at 37° 
 
3.2.2 DNA techniques 
3.2.2.1 Purification of plasmid DNA 
Plasmid DNA was purified in small scale (minipreps) with the QIAGEN plasmid 
extraction kit (QIAGEN, Hilden, Germany) and in large scale (maxiprep) with the 
(Promega Germany) according to the manufacturer’s protocol. 
 
3.2.2.2 Estimation of DNA concentration  
The purified DNA concentration and purity was determined by measuring the UV 
absorbance at 260 and 280 nm. The concentration of the DNA was calculated using 
the formula 1 OD260 = 50 µg/ml dsDNA or 33 µg/ml ssDNA. The purity of the DNA 
was determined using the OD260/OD280 ratio, with a ratio of ca. 1.8 indicating a low 
degree of protein contamination. 
 
3.2.2.3 Primer design 
While the forward primers were provided by Armin Baiker, the reverse primers were 
designed by using pDRAW32 software. The internal forward primer used comprises 
12bp of the attB1, a translational consensus sequence (KOZAK) and 20bp of the 
respective 5’ specific ORF sequence. The internal reverse primer contains 12bp of 
the attB2 sites, the 3’ end of the respective ORF with no stop codon and 20bp 
sequence complementary to the coding region.  
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3.2.2.4 Nested Polymerase Chain Reaction 
All the single ORFs in the VZV were amplified by two rounds of PCR (nested PCR). 
The primer design for the first round of PCR were described in 3.2.2.3. The nested 
PCR consists of two steps. In the first step the individual genes were amplified by a 
pair of specific forward and reverse primers. For the second PCR, the amplicon of the 
first PCR was used as a template. In the second round of PCR the full length attB site 
was added to the respective PCR fragment. All PCR amplifications were performed 
using the EXPAND LONG Polymerase (Roche, Mannheim, Germany). The typical 
reaction was performed in a 50 µl volume as shown in Figure 12. 
 
Reaction mixture of  the first PCR: 
10X buffer  5 µl 
10mM dNTPs 1 µl 
1unit expand long polymerase 1 µl 
gene specific For Primer (10pmol/U) 2 µl 
gene specific Rev Primer ( 10pmol/U) 2 µl 
VZV template DNA(100ng) 8 µl 
Sterile water 31 µl 
 
Typical reaction conditions: 
 
1 -   95°C for 2 min (initial denaturation) 
2 -   95°C for 30 sec (denaturation) 
3 -   55°C for 30 sec (annealing) 
4 -   68°C for [1000bp x = 1 min] (extension) 
5 -   15 – 20 cycles 
6 -   68°C final extension 
For some of the PCR fragments, the annealing temperature had to be varied 
(decreased 2 to 5°C) in order to get better amplification products.  
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1st step          2nd step                          3rd step 
 
 
 
 
 
       
  (ca. 10-15 cycles) 
 
Figure 12: The schematic diagram representing the 1
st
 and 2
nd
 PCR rounds 
 
Reaction mixture of the second PCR: 
10X buffer 5 µl 
10mM dNTPs 1 µl 
1unit  expand long polymerase 1 µl 
attB1 Primer (10pmol/U) 2 µl 
attB2 Primer ( 10pmol/U) 2 µl 
first PCR product DNA(100ng) 8 µl 
Sterile water 31 µl 
 
The amplification conditions used for the second PCR were identical to the first PCR 
(see above). After PCR amplification, the resulting products were separated on an 
0.8% agarose gel by electrophoresis. 
 
3.2.2.5 Agarose gel electrophoresis 
PCR products, restricted fragments and plasmids were analysed by agarose gel 
electrophoresis in 1x TAE. An agarose concentration between 0.8 to 1.5% was used 
for analysis depending on the molecular weight of the DNA to be analysed. The 
agarose was solubilised in 1X TAE by heating in a microwave oven and 0.25 µg/ml 
(2.5 µl stock to 100 ml) of ethidium bromide was added before casting the gels. Gels 
of different sizes were cast based on the number of DNA samples. The DNA samples 
Initial denaturation                                       
94°C, 2 min 
 
Denaturation                                    
95°C, 30 sec 
 
Annealing                                     
55°C – 30 sec 
 
Synthesis                               
72-68°C,  
( for 1000bp - 1min = X ) 
 
Final synthesis                                    
72°C, X+5min 
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to be analysed were mixed with 6x loading dye. Gels were run from anode to cathode 
at 120 to 160 V based on the length of the gel. DNA was detected using UV light, 
=254 nm or =366 nm to cut out specific fragments. 
Loading Buffer (6x in water)  MBI Fermentas, St. Leon-Rot, Germany 
 
50x TAE (1l) 
50 x (pH 8.4) 1 x (pH 8.0)  
2 M Tris 40 mM Tris   242 g 
Acetic acid (glacial) 20 mM acetic acid  57.1 ml 
0.05 M EDTA 1 mM EDTA 100 ml 0.5M EDTA  
 
Ethidium Bromide (stock): 10 mg/ml 
 
3.2.2.6 Isolation of PCR fragments from agarose gels 
The DNA fragments obtained by PCR and separated on 0.8% agarose gels and 
determined to be of the correct size were cut out from the gel by using a sharp razor 
blade. The PCR fragments were purified by using the QIAGEN Gel extraction kit 
(QIAGEN, Hilden, Germany) according to the manufacturer’s protocol.  
 
3.2.2.7 Recombinational cloning of the PCR fragments 
To clone the resulting PCR product into the pDONR207, a BP reaction was 
performed. A typical BP reaction was set up in a reaction volume of 5 µl. 
 
purified PCR product 2-3 µl 
pDONR 207  1 µl 
BP Clonase 1 µl 
Ampuwa water 1 µl 
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The reaction mixture was incubated at room temperature for 4 to 5 hours and then 
transformed into E. coli DH10B by electroporation. Bacteria were plated on selective 
media. Positive clones were analysed by plasmid purification and restriction analysis. 
Note: the pDONR207 vector containing a subcloned viral ORF was renamed in 
pENTR207 (Gateway® nomenclature). The original pDONR207 comprised attB sites, 
whereas the recombination product comprised attL sites. 
To subclone the viral ORFs from the pDONR207 into a destination vector, an 
LR reaction is performed. The LR reaction was set up in a reaction volume of 5 
µl.  
 
purified entry vector 1 µl 
Destination vector 1 µl 
LR Clonase  1 µl 
Ampuwa water 2 µl 
 
The reaction mixture was incubated at 37°C for 2 hours and then transformed into E. 
coli DH10B by electroporation. Positive clones were analysed by plasmid purification 
and restriction analysis. 
 
3.2.2.8 Isolation of plasmid DNA in 96 well format 
Bacterial colonies were picked from LB-plates and an overnight culture was grown at 
37°C in a 96-well block containing LB supplemented with gentamycin. The next day, 
the 96-well block was centrifuged for 10 min at 4000 rpm to harvest the cells. After 
discarding the supernatant, cells were resuspended thoroughly in 300 µl of 
resuspension buffer. After that, lysis buffer was added to the cell lysate and mixed by 
inverting the 96-well block several times. After incubation of the lysates for 5 min at 
room temperature, 300 µl of neutralization buffer was added. The lysate was mixed 
again by inversion, and incubated on ice for 10 min. After this step, the cells in the 96 
well block were centrifuged for 30 min at 4000 rpm. Then, 800 µl of supernatant was 
transferred into a fresh 96-well block. After addition of 580 µl of isopropanol, the cells 
were kept at –20°C for one hour and then centrifuged for 45 min at 4000 rpm at 4°C 
to precipitate the DNA. The pelleted DNA was washed briefly with 500 µl of 75% 
ethanol and then air-dried for 20 min. Finally 50µl of sterile water was added to 
resuspend the plasmid DNA. 
 40 
3.2.2.9 Restriction analysis of pENTR207 (entry vector) clones 
The restriction digest of the pENTR207 entry clones was set up in a reaction volume 
of 30 µl.  
 
Reaction mixture: 
pENTR207 miniprep DNA     5 µl 
buffer 4     3 µl 
RNase (1 mg/ml)   0.5 µl 
BSA   0.3 µl 
BanII    0.3 µl 
sterile water 20.9 µl 
 
The restriction analysis was performed using the BanII enzyme, since BanII 
restriction releases the subcloned ORF fragment out of the pENTR207 vector 
backbone. The restriction mixture was placed in 96 well ELISA plates, sealed with 
plastic tape, and incubated for 3 hours at 37°C. After restriction, the plasmid DNAs 
were separated on a 0.8% agarose gel, visualized and documented. 
 
3.2.2.10 Restriction analysis of destination vector clones 
The restriction digest of the pENTR207 entry clones was set up in a reaction volume 
of 30 µl.  
 
Reaction mixture: 
miniprep DNA     5 µl 
buffer      3 µl 
RNase (1 mg/ml)   0.5 µl 
BSA   0.3 µl 
HindIII   0.3 µl 
XbaI   0.3 µl 
sterile water 20.9 µl 
 
The restriction analysis was performed by HindIII and XbaI since these enzymes 
release the subcloned ORF fragment out of the pENTR207 vector backbone. The 
restriction mixture was placed in 96 well ELISA plates, sealed with plastic tape, and 
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incubated for 3 hours at 37°C. After restriction, the plasmid DNAs were separated on 
a 0.8% agarose gel, visualized and documented. 
 
3.2.3 Tissue culture 
3.2.3.1 MeWo cell culture and infection with p-Oka strain 
MeWo cells were cultured on MEM medium supplemented with 10% fetal calf serum, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and µg/ml fungitone 
at 37°C and 5% CO2. The MeWo cell cultures were propagated by detaching them 
with trypsin and seeding the cells in 1:4 ratios. By adding p-Oka infected MeWo cells 
to uninfected MeWo cells at a ratio of 1:50 the virus was propagated. 
 
3.2.3.2 Immunofluorescence microscopy 
Uninfected MeWo and infected MeWo cells were cultured in the ratio of 1:50 on glass 
coverslips for 48h. At 48h post infection coverslips were washed once with phosphate 
buffered saline (PBS) and fixed for 15min using 2% formaldehyde (FA). Cells were 
washed twice with PBS. Permeabilization was done by incubation with icecold PBS 
containing 0.5% TritonX-100 for 5min followed by a wash step with PBS. After this, 
the cells were blocked with PBS containing 10% goat serum and 0.3% TritonX-100 
for 1h. Then the cells were incubated with primary antibody (monoclonal antibody 
supernatant obtained from positive B cell fusions) supplemented with 3% goat serum 
and 0.3% TritonX-100 for 3h at RT. The cells were washed thrice for 15 min and 
subsequently incubated with secondary antibody (goat anti-mouse immunoglobulin G 
[IgG]-Alexa Fluor 488-conjugated antibody) diluted 1:400 in PBS containing 3% goat 
serum and 0.3% TritonX-100. Nuclei were counterstained with DAPI (4-6 diamidino-
2-phenylindole) and the cells were washed thrice for 15min using PBS. Finally, 
coverslips were mounted onto glass slides with mounting medium (vectra shield) and 
analysed using a fluorescence microscope at a magnification of 40X. 
 
3.2.4 Protein Techniques 
3.2.4.1 Purification of recombinant His-tagged VZV proteins 
20 ml of overnight culture of BL21 RIL cells containing VZV ORFs in expression 
vectors were inoculated into 1l of selective LB medium (50 µg/ml of ampicillin, 50 
µg/ml of chloramphenicol) were grown at 37°C until an OD600 of 0.6 was reached. 10 
ml of 1mM IPTG was added and cells were cultured for 4 to 6 hours at 37°C. 
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Bacterial cells were harvested by centrifugation for 30 min at 4000 rpm and the pellet 
was resuspended in 40 ml of lysis buffer (50mM Tris-HCl pH 6.8, 0.3M NaCl, 6M 
guanidinium hydrochloride, 5mM imidazole). Then the bacterial suspension was 
sonicated 3 times for 2min (output control level 6) on ice and shaken at room 
temperature for 1h. The bacterial suspension was centrifuged for 30 min at 16,000g 
and the supernatant was collected by centrifugation. Simultaneously 1ml of Ni-NTA 
agarose beads were equilibrated by washing with Urea buffer w/o imidazole. 
Equilibrated Ni-NTA agarose beads were incubated with supernatant for 30min by 
shaking and the suspension was loaded onto the column. Then the flowthrough was 
discarded and the column was washed 4x using 10ml of Urea buffer w/o imidazole, 
3x with 10ml of Urea buffer containing 10mM imidazole (50mM Tris-Hcl pH 6.8, 0.3M 
NaCl, 8M urea, 10mM imidazole) and 2x with 10ml of Urea buffer containing 50mM 
imidazole (50mM Tris-Hcl pH 6.8, 0.3M NaCl, 8M urea, 50mM imidazole). Finally the 
protein was eluted 3x with 500 µl of elution buffer (50mM Tris-Hcl pH 6.8, 0.3M NaCl, 
4M urea, 450mM imidazole). Eluted fractions and samples of solutions were 
analysed by SDS-PAGE. 
 
Urea Buffer w/o imidazole (1l) 
50 mM Tris-Hcl pH 6.8 6.05 g 
0.3 M NaCl    18 g 
8 M urea  180 g 
 
3.2.4.2 Sample preparation for SDS-PAGE 
Bacterial cell lysates containing expressed proteins, purified proteins, MeWo cell 
lysates either uninfected or VZV infected were resuspended in 2xSDS protein sample 
buffer and heated for 5 min at 95°C. After cooling the samples were centrifuged for 1 
min at 14,000 rpm and stored at -20°C. 
 
3.2.4.3 SDS-PAGE 
Gel electrophoresis was performed with minigels using the Protean II system (Bio-
Rad) with 6 to 15% gels (80 x 50 x 1 mm). The separating gel was mixed and poured 
between the glass plates and covered with distilled water. After polymerisation the 
distilled water was removed. Then the stacking gel was poured and the comb was 
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inserted. The samples were loaded on the gel along with the protein marker. The 
separation was done for 1 hour at 120 V. 
 
Separation gel: 
components 6% 8% 12% 15% 
Acrylamide/ Bisacrylamide (37.5:1) 2.68 ml 2.35 ml 1.67 ml 1.17 ml 
1.5 M Tris pH 8.8 1.25 ml 1.25 ml 1.25 ml 1.25 ml 
10 % SDS    50 µl    50 µl    50 µl    50 µl 
Distilled water     1 ml 1.32 ml   2.0 ml  2.5 ml 
10 % APS    25 µl    25 µl    25 µl     25 µl 
TEMED   2.5 µl   2.5 µl   2.5 µl   2.5 µl 
 
Stacking gel: 
Components 5% 
Acrylamide/ Bisacrylamide (37.5:1) 1.35   ml 
1.5 M Tris pH 8.8 0.625 ml 
10 % SDS     25  µl 
Distilled water 1.53   ml 
10 % APS 12.5   µl 
TEMED     2.5 µl 
 
Electrophoresis buffer (10x) (1l): 
50 mM Tris     60.6 g 
384 mM Glycine   288.0 g 
0.1% SDS     20.0 g 
 
3.2.4.4 Western Blot 
The proteins separated on the SDS-Gel were transferred to nitrocellulose 
membranes using the Trans-Blot wet Transfer Cell (Bio-Rad). The SDS-gel was 
directly placed on the nitrocelluose membrane and two pieces of Whatman filter 
paper were placed on either side of them. The internal air bubbles were removed by 
rolling the smooth glass rod on the top of the sandwich. The proteins on the gel were 
transferred to the membrane at 120 V for one hour. Proteins transferred were 
confirmed by incubating the nitrocelluose membrane in ponceau solution. The 
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nitrocelluose membrane was blocked in 5% milk solution for one hour. Then the 
membrane was incubated with primary antibody for one hour. The membrane was 
washed thrice with PBS for 10 min. After that, the membrane was incubated with 
horse radish peroxidase conjugated goat anti-mouse secondary antibody (1:2500 in 
PBS) and washed three times with PBS for 30min. The blotted proteins were 
visualized by ECL according to the manufacturer’s instructions. The membrane was 
exposed to BIOMAX-MR autoradiography films for different time periods and films 
were developed using an automatic film developing machine. 
 
Transfer buffer (1l) 
Tris base   5.8 g 
Glycine   2.9 g 
SDS 0.37 g 
Methanol 200 g 
H2O ad 1l 
 
Ponceau solution (100 ml) 
Ponceau S   0.5 g 
Glacial acetic acid    1  ml 
H2O 98.5 ml 
 
3.2.5 Generation of monoclonal antibodies 
3.2.5.1 Immunization 
50 micrograms of protein or peptide were dissolved in PBS and mixed with the 
complete Freund´s adjuvant (CFA) in a ratio of 1:1 (e.g. 400 µl of PBS / protein + 400 
ul CFA). Mouse were immunized subcutaneously. After 15 days the same amount of 
protein mixed with incomplete Freund´s adjuvant was mixed and used for 
immunization of the mouse by injecting 2/3 of the volume subcutaneously and 1/3 
intraperitoneally. After 10 days blood was drawn from the tail vein and the titer of 
antibodies in the sera was determined by ELISA. In the case of a low titer, a 3rd 
immunization was applied). 3 to 5 days before the spleen was removed for 
hybridoma fusion mice were injected with 50µg of protein dissolved in PBS (“boost“). 
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3.2.5.2 Fusion 
SP2/o cells were expanded 5 days before the scheduled fusion. The spleen was 
isolated under sterile conditions and homogenized in cold RPMI. Then the cell 
suspension was centrifuged at 1500 rpm for 5 min at RT. The supernatant was 
removed and the cells were resuspended in 1 ml of RPMI. In the same time SP2/o 
cells were harvested, centrifuged, resuspended in 10 ml of warm RPMI w/o HEPES 
and counted. SP2/o cells and splenocytes were then mixed in a 1:1 ratio, centrifuged 
and the supernatant was removed. Blue cap containing cells were placed into the 
glass, prefilled with warm water in the 37°C water bath. In a dropwise manner 1 ml of 
pre-warmed PEG was added throughout 1 minute, mixing it continuously. After the 
addition of PEG, mixing was continued for one more minute. In a dropwise manner 1 
ml of pre-warmed RPMI was added throughout 1 minute, continuously mixing. Then 
again 1 ml of RPMI (w/o HEPES) was added. Add 7 ml of warm RPMI (w/o HEPES) 
in a dropwise manner throughout 2-3 min. Then the cells were centrifuged at 800 rpm 
for 5 min. Supernatant was removed and 10ml of 20% warm RPMI with HAT was 
added and care is taken not to resuspend the cells. The suspension is aliquoted into 
96-well plates (200 ul/well) and the cells were grown in the incubator (37°C, 5% 
CO2). The wells were observed to follow the growth of hybridoma cells by 
microscopy. Then the cells were feeded for every few days by replacing the old 
media with new 20% RPMI containing HAT. The supernatant of growing hybridomas 
were tested after 12 days post fusion by ELISA. Finally, motherwells that recognised 
the protein of interest were expanded. 
 
3.2.5.3 Cloning of Mother wells 
For cloning of mother well clones, the cells were taken from 1 well of a 24-well plate 
and counted. The cell number was adjusted by serial dilution so that a) 30 cells/well, 
b) 3 cells/well, c) 0.3 cells/well were plated per well (volume per well is 200 ul). Each 
well in the 96-well plate was filled with these suspensions. One half of the 96-well 
plate was filled with suspension a) while the other half was filled with suspension b), 
suspension c) was again plated on a half of a 96-well plate. The cells were placed in 
the incubator, their growth was observed under the microscope and finally, the 
supernatant produced by hybridomas singled out on 0.3 cells / plate were tested by 
ELISA. 
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3.2.5.4 ELISA 
ELISA is performed on plates coated with the antigen of interest. Supernatant of the 
growing hybridoma is added to the coated plates in duplicates and incubated for 1h 
at RT. Excess of antibodies is washed off and secondary antibody is added (goat 
anti-mouse IgG conjugated to peroxidase) and incubated for 1h at RT. After washing, 
the ELISA plates were incubated with substrate (OPD pill is dissolved in 50 ml of 
citrate buffer and 50 ul of 6% H2O2) for 5 to 10 min in the dark. The reaction is 
stopped by the addition of 50 ul of 1M H2SO4 (per well). ELISA plates were read on 
the spectrophotometer (492 nm/630 nm). 
 
3.2.6 Epitope mapping 
Peptides consisting of 15 residues were spotted on the cellulose membrane with 
each peptide shifted in sequence by 3 residues. Subsequently, the membrane was 
first incubated with methanol for 10min, then washed thrice with TBS-T for 10min. 
Unspecific binding was blocked for 3h with 2% milkpowder in 0.2% TBS-T. Followed 
by this, the membrane was washed for 10min with TBS-T (0.05% Tween) and 
incubated with primary antibody for 3h (monoclonal antibody supernatant obtained 
from positive B cell fusions raised against VZV ORFs). Then the membrane was 
washed thrice for 10min using TBS-T (0.05% Tween). After this, incubation with 
secondary antibody was performed for 1.5h (goat anti-mouse antibodies conjugated 
to alkaline phosphatase at a dilution of 1:3000) and the membrane was washed 
thrice for 10min using PBS-T. The immunodominant region (epitope) was detected 
using the ECL detection system (Amersham-Pharmacia/GE Healthcare) according to 
the manufacturer’s instructions. Finally, the membrane was exposed to BIOMAX-MR 
autoradiography films for different periods of time and films were developed using an 
automatic film developing machine.  
 
3.2.7 Computer-assisted prediction of nuclear transport signals 
To predict the nuclear localisation of all VZV proteins, the presence of putative 
nuclear localisation signals (NLS) was determined using 
http://cubic.bioc.columbia.edu/predictNLS/ (NLS) and http://www.expasy.org/cgi-
bin/nicedoc.pl?PDOC00015 (bipartite NLS). The presence of putative nuclear export 
sequences (NES) was determined using http://www.cbs.dtu.dk/services/NetNES/. 
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4. Results 
 
4.1 Generation of VZV expression libraries 
To generate antibodies for all ORFs of VZV, expression libraries of VZV were 
constructed where the encoded proteins were equipped with an N-terminal His, N-
terminal MBP, N-terminal GST, or C-terminal His tag.  
 
4.1.1 Amplification of VZV ORFs by nested PCR 
For the construction of the VZV ORFeome, primers were designed for amplification of 
all 70 ORFs in full length. In addition, primers were also designed to amplify 
fragments (29) of some of the ORFs. ORFs with cytoplasmic or luminal domains of 
transmembrane proteins or subfragments of very long genes (>3kb) were selected 
for fragmented amplification.  
First, each ORF was amplified by nested PCR in two steps. In the first PCR, the ORF 
was amplified by using gene-specific forward and reverse primers containing partial 
attB regions. A characteristic primer pair is shown in Figure 13. The second PCR was 
performed by using complete attB (common to all ORFs) primers in order to attach 
full length attB sites to the viral genes pre-amplified in the first PCR. Then the 
amplified PCR products were separated on 0.8% agarose gels and the pre-
determined size of the amplicons was verified. Finally, the amplified and verified PCR 
products containing complete attB sites were compatible for Gateway® cloning. All 
the 70 ORFs along with 29 partial ORFs (some encoding N and C terminal domains) 
comprising 99 amplicons in total, were amplified successfully (32). 
 
 
 
Figure 13: A PCR-product with VZV specific forward and reverse primers and partial attB sites. 
 
The sequence on the left hand side represents the forward primer, the sequence in 
black represents the complementary sequence to the respective ORF, indicated in 
green is the start codon while the sequence in red represents the partial attB1 region. 
The sequence on the right hand side is the reverse primer. In black the sequence 
complementary to the respective ORF is indicated while the partial attB2 region is 
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shown in red. By adding primers containing complete attB regions in the second PCR 
round the respective ORFs were amplified.  
 
4.1.2 Construction of the Gateway® compatible ORFeome in the     
pDONR207 vector 
After PCR amplification of all VZV genes they were cloned into the Gateway® 
compatible pDONR207 vector by BP recombinational cloning. The BP reaction 
mixture was transformed into DH10B cells and selected on LB plates containing 
gentamycin. The positive clones were screened by isolating plasmids from DH10B 
cells and analysing them by restriction digest using the BanII enzyme (Figure 14). 
Finally, 99 clones encoding all VZV ORFs either in full length or fragments were 
cloned into the vector pDONR207. The VZV ORFeome cloned in pDONR207 (entry 
vector) is also called the VZV entry library. The positive clones were verified by 
sequencing. 
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Figure 14: Restriction analysis of the VZV entry library. The restriction analysis of selected 
pENTR207 plasmids containing the subcloned viral ORFs or ORF fragments is displayed. The 
restriction analysis was done by BanII digestion, and analysed on a 1% agarose gel. The arrow 
represents the vector backbone and DNA ladder is as follows from the bottom (0.25, 0.5, 0.75, 1, 1.5, 
2, 2.5, 3, 3.5, 4, 5, 6, 8 and 10 kbp). 
 
4.1.3 Sequence analysis of the VZV ORFeome in pDONR207 vector 
The entry clone sequences were analysed using the pDRAW32 software. The 
respective individual ORF sequences were translated into protein sequences, and 
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compared to the “original” viral protein sequences available in the NCBI database. All 
the 99 entry clones were found to be correct by sequencing (100 % alignment to the 
“original” DNA sequence). 
 
4.1.4 Subcloning of entry clones into expression vectors  
The entry clones of the VZV ORFeome can be cloned into any Gateway®  
compatible destination vector. For protein expression of VZV proteins in E. coli cells, 
an LR reaction was performed to subclone the VZV ORFeome into the Gateway®  
compatible pETG expression vectors providing N-terminal His, N-terminal MBP, N-
terminal GST, or C-terminal His tags to the protein of interest. The positive clones 
were screened by isolating plasmids from DH5α cells and analysing them by 
restriction digest using HindIII and XbaI enzymes. Thus, three complete expression 
libraries encoding Orfs with N-terminal His, N-terminal MBP, N-terminal GST and a 
partial library encoding C-terminal His tagged proteins were constructed. As the 
expression libraries contain different resistance genes, the subcloning could be 
performed in a one-step reaction. The status of the VZV ORFs that were cloned from 
the VZV ORFeome to four different expression vectors (N-His, N-MBP, N-GST and 
C-His) is listed in Table 4. 
 
Table 4: Status of clones in expression libraries 
VZV (ORF) 
position 
(nt) pDONR207    N-His   N-MBP    N-GST    C-His 
              
Orf1 1-327        XX        XX        XX        XX        XX 
Orf1N 1-222        XX        XX        XX        XX        XX 
Orf2 1-717        XX        XX        XX        XX        ---- 
Orf3 1-540        XX        XX        XX        XX        XX 
Orf4 1-1359        XX        XX        XX        XX         No 
Orf5 1-1023        XX        XX        XX        XX        XX 
Orf5 F 396-642        XX        XX        XX        XX         No 
Orf6 1-3252        XX        XX        XX        XX        XX 
Orf7 1-780        XX        XX        XX        XX        XX 
Orf8 1-1191        XX        XX        XX        XX        XX 
Orf9 1-909        XX        XX        ----        XX        ---- 
Orf9a 1-264        XX        XX        XX        XX        XX 
Orf9a N 1-159        XX        XX        XX        XX        XX 
Orf10 1-1233        XX        XX        XX        XX        XX 
Orf11 1-2460        XX        XX        XX        XX        XX 
Orf12 1-1986        XX        XX        XX        XX        XX 
Orf12 N 1-894        XX        XX        XX        XX        XX 
Orf12 C 1065-1986        XX        XX        XX        XX        XX 
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Orf13 1-906        XX        XX        XX        XX        XX 
Orf14 1-1683        XX        XX        XX        XX        XX 
Orf14 N 1-1593        XX        XX        XX        XX        ---- 
Orf15 1-1221        XX        ----        ----        ----        ---- 
Orf15 N 1-141        XX        XX        XX        XX        ---- 
Orf15 F 609-810        XX        XX        XX        XX        XX 
Orf16 1-1227        XX        XX        XX        XX        XX 
Orf17 1-1368        XX        XX        XX        XX        XX 
Orf18 1-921        XX        XX        XX        XX        XX 
Orf18 N 1-450        XX        XX        XX        XX        XX 
Orf18 C 507-921        XX        XX        XX        XX        XX 
Orf19 1-2328        XX        XX        XX        XX        XX 
Orf20 1-1452        XX        XX        XX        XX        XX 
Orf21 1-3        XX        ----        ----        XX        ---- 
Orf21.1 1-1000        XX        XX        XX        XX        ---- 
Orf22 N 1-4119        XX        XX        XX        XX        ---- 
Orf23 1-708        XX        XX        XX        XX        ---- 
Orf24 1-810        XX        XX        XX        XX        ---- 
Orf24 N 1-735        XX        XX        XX        XX        ---- 
Orf25 1-471        XX        XX        XX        XX        ---- 
Orf26 1-1758        XX        XX        XX        XX        ---- 
Orf27 1-1002        XX        XX        XX        XX        XX 
Orf28 1-3585        XX        XX        XX        XX        ---- 
Orf29.1 1-3615        XX        XX        XX        XX        ---- 
Orf29.3          XX        XX        XX        ----        ---- 
Orf30 1-2313        XX        XX        XX        XX        ---- 
Orf31 1-2607        XX        XX        XX        XX        ---- 
Orf31 N 1-2175        XX        XX        XX        XX        ---- 
Orf31 C 2250-2607        XX        XX        XX        XX        ---- 
Orf32 1-432        XX        XX        XX        XX        ---- 
Orf33 1-1818        XX        XX        XX        XX        ---- 
Orf33.5 909-1818        XX        XX        XX        XX        ---- 
Orf34 1-1740        XX        XX        XX        XX        ---- 
Orf35 1-777        XX        XX        XX        XX        ---- 
Orf36 1-126        XX        XX        XX        XX        XX 
Orf37 1-2526        XX        XX        XX        XX        ---- 
Orf37 N 1-2409        XX        XX        XX        XX        XX 
Orf38 1-1626        XX        XX        XX        XX        XX 
Orf39 1-723        XX        XX        XX        XX        ---- 
Orf39 N 1-237        XX        XX        XX        XX        ---- 
Orf40 1-4191        XX        XX        XX        XX        ---- 
Orf41 1-951        XX        XX        XX        XX        ---- 
Orf42 1-966        XX        XX        XX        XX        XX 
Orf43 1-2031        XX        XX        XX        XX        ---- 
Orf43 C 141-2031        XX        XX        XX        XX        ---- 
Orf44 1-1092        XX        XX        XX        XX        ---- 
Orf45 1-1071        XX        XX        XX        XX        XX 
Orf46 1-600        XX        XX        XX        XX        XX 
Orf47 1-1533        XX        XX        XX        XX        XX 
Orf48 1-1656        XX        XX        XX        XX        XX 
Orf49 1-246        XX        XX        XX        XX        XX 
Orf50 1-1308        XX        XX        XX        XX        ---- 
Orf50 C 1074-1308        XX        XX        XX        XX        XX 
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Orf51 1-2508        XX        XX        XX        ----        ---- 
Orf52 1-2316        XX        XX        XX        ----        ---- 
Orf53 1-996        XX        XX        XX        XX        XX 
Orf54 1-2310        XX        XX        XX        XX        ---- 
Orf55 1-2646        XX        XX        XX        XX        ---- 
Orf56 1-735        XX        XX        XX        XX        ---- 
Orf56 C 183-735        XX        XX        XX        XX        XX 
Orf57 1-216        XX        XX        XX        XX        XX 
Orf58 1-666        XX        XX        XX        XX        XX 
Orf59 1-918        XX        XX        XX        XX        ---- 
Orf60 1-480        XX        XX        XX        XX        ---- 
Orf60 C 87-480        XX        XX        XX        XX        ---- 
Orf61 1-1404        XX        XX        XX        XX        ---- 
Orf62 1-3933        XX        XX        XX        XX        ---- 
Orf63 1-837        XX        XX        XX        XX        ---- 
Orf64 1-543        XX        XX        XX        XX        ---- 
Orf65 1-309        XX        XX        XX        XX        ---- 
Orf65 N 1-222        XX        XX        XX        XX        ---- 
Orf66 1-1182        XX        XX        XX        XX        ---- 
Orf67 1-1065        XX        XX        XX        XX        ---- 
Orf67 N 1-816        XX        XX        XX        XX        ---- 
Orf67 C 882-1065        XX        XX        XX        XX        ---- 
Orf68 1-1872        XX        XX        XX        XX        ---- 
Orf68 F 72-1611        XX        XX        XX        XX        ---- 
Orf68 C 1680-1872        XX        XX        XX        XX        ---- 
S/L          XX        XX        XX        XX        ---- 
S/L-C 1-954        XX        XX        XX        XX        ---- 
S/L-MKKVSV 234-954        XX        XX        XX        XX        ---- 
 
4.2 Expression and purification of VZV proteins 
Compared to other human herpes viruses, VZV research is progressing slowly. In 
order to study VZV proteins both biochemically and functionally, it is necessary to 
generate monoclonal antibodies against all VZV proteins. These monoclonal 
antibodies are indispensable molecular detection tools used in a vast number of 
techniques. To raise mabs, first of all, the expression of all VZV proteins cloned in N-
His, C-His and N-MBP expression vectors was verified. To test for expression, the 
vectors containing VZV ORFs with N-His, C-His and N-MBP tags were transformed 
into bacterial BL21RIL cells. Single bacterial colonies were grown in liquid LB media 
supplemented with antibiotics and at an OD600 of 0.5 induced with 1 mM IPTG. 
Expression of the VZV proteins was verified by Western blotting using α-His, α-MBP, 
or anti-GST antibodies. Once the expression was confirmed, the positively tested 
bacterial strains were cultured in large scale (1 liter). Bacterial pellets were collected, 
taken up in lysis buffer and sonified. After centrifugation of the debris, His- and MBP-
tagged proteins were purified from the supernatant via affinity chromatography using 
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Ni-NTA-agarose or amylose beads. The purified proteins were analysed once again 
with α-His and α-MBP antibodies. All proteins of the VZV genome could be 
expressed while only 65 VZV proteins could be purified efficiently. Of the 65 VZV 
purified proteins, 36 VZV proteins were purified by using an N-terminal His-tag, 14 
VZV proteins were purified based on their C-terminal His-tag, and 15 VZV proteins 
were purified by N-terminal MBP tags (Table 5). 
 
Table 5: Status of purified proteins with different tags 
Type of tag No of proteins 
N-His 36 
C-His 14 
N-MBP 15 
 
4.3 Generation of monoclonal antibodies against the VZV proteome 
4.3.1 Immunisation of mice with purified proteins and peptides 
To generate monoclonal antibodies, purified VZV proteins were used for 
immunisation of Balb/c mice. Per immunization 50 micrograms of protein were 
injected. Normally two doses were given but if the antibody titer remained below the 
titration level a third booster dose was applied. This was done in collaboration with 
Stipan Jonjic, University of Rijeka, Croatia. Mice were immunised with 65 VZV 
proteins equipped with different tags (Table 6). In addition, for 6 ORFs peptides were 
generated and used for immunization. Out of 65 VZV proteins, 36 VZV proteins 
contained N-terminal His tags, 14 VZV proteins contained C-terminal His tags and 15 
VZV proteins contained MBP tags. For ORF37 and ORFS/L (ORF0), immunisation 
was done using N-terminally His-tagged proteins as well as peptides. The hybridoma 
supernatants that were tested positive in ELISA (against specific antigens used for 
immunisation) were screened finally both by Western blotting and indirect 
immunofluorescence.  
 
Table 6: Status of immunisation 
Material used for 
immunisation 
No of proteins 
N-His 36 
C-His 14 
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N-MBP 15 
peptides 6 
 
4.3.2 Screening of hybridoma supernatants by Western blotting  
The hybridoma supernatants of mother wells (MW) and subclones that were tested 
positive on ELISA were screened again by Western blotting to confirm and finalise 
that the subclones are producing antibodies specific to VZV ORFs. Infected and 
uninfected MeWo cell lysates were generated, run in parallel on SDS gels and blotted 
onto nitrocellulose membrane. Subsequently, the nitrocellulose membranes were cut 
into small stripes so that each stripe contained both infected and uninfected MEWO 
lysates adjacently. These stripes were first incubated with hybridoma supernatants 
tested positively on ELISA and subsequently with horse radish peroxidase 
conjugated goat α-mouse secondary antibodies. The Western blots were processed 
by ECL and detected using a BIOMAX-MR film.  
Antibodies in most of the tested hybridoma supernatants decorated bands that 
correlated with the predicted size of the respective VZV ORF. The predicted 
molecular weight (MW) of the proteins is summarized in Table 8. By Western blot 
screening we identified positive hybridoma clones for 57 VZV ORFs, the 
corresponding pictures are shown in Figure 15 with the exception of ORF60. In total, 
47 of the 57 VZV ORFs (83%) migrated at the predicted MW, and the remaining 10 
(17%) migrated aberrantly. This aberrant migration could be due to protein 
proteolysis, to alternative splicing, to posttranslational modification, or simply mixup 
of samples. Sofar, we have identified 190 antibodies produced by hybridoma clones 
which specifically detect VZV proteins in Western blotting (Table 9). 
 
Figure 15: Testing of hybridoma supernatants with cell lysates of infected and uninfected 
MeWo cells by Western blot. Hybridoma supernatants were tested before and after subcloning to 
identify specific positive clones for all VZV ORFs. Lysates of MeWo cells infected with pOKA (1:50 
uninfected to infected cells for 48hrs) and uninfected MeWo cells were generated and applied to SDS-
PAGE adjacent to each other. Proteins were separated electrophoretically and subsequently 
transferred to nitrocellulose membranes. The membranes were cut into small stripes, each stripe 
containing both infected (as indicated by +) and uninfected protein lysates (as indicated by -). Each 
stripe was incubated with a supernatant containing primary antibodies originating from various 
hybridoma clones and then incubated with secondary peroxidize-conjugated goat anti-mouse 
antibodies. Finally, the stripes were processed by ECL and exposed to BIOMAX-MR films. 
Specific bands were indicated by stars. The molecular weight marker in kilodalton (MW in kDa) is 
indicated on the left. Depending on the predicted size of the VZV ORF, infected and uninfected MeWo 
cell lysates were run on different concentrations of gels as indicated in colored ORFs (blue: 6%, pink: 
8%, green: 12%, black15%). 
 54 
ORF 7
20
30
40
50
kd
*
60
10
ORF 10
20
30
40
50
kd
*
60
10
ORF 3
20
30
40
50
kd
*
60
10
- + - +
- +
ORF 5
20
30
40
50
kd
*
60
10
- +
ORF 2
20
30
40
50
kd
*
60
10
- +
ORF 4
20
30
40
50
kd
*60
10
- +
ORF 6
70
80
90
100
kd
*120
50
160
- +
ORF 8
20
30
40
50
kd
*
60
10
- +
ORF 9
20
30
40
50
kd
*
60
10
- +
ORF 11
70
80
90
100
kd
*
120
50
160
- +
ORF 12
20
30
40
50
kd
*60
10
- +
ORF 13
20
30
40
50
kd
*
60
10
- +
ORF 14
20
30
40
50
kd
*60
10
- +
70
ORF 18
20
30
40
50
kd
*
60
10
- +
ORF 16
20
30
40
50
kd
*
60
10
- +
70 70 70 70
70
70 7070
7070
70
70
 
Figure 15 (for legend see above) 
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4.3.3 Screening of hybridoma supernatants by indirect 
immunofluorescence 
The hybridoma supernatants of mother wells (MW) and subclones that were tested 
positive on ELISA were screened again by indirect immunofluorescence in parallel to 
Western blotting to confirm and finalise the subclones that are producing antibodies 
specific to VZV ORFs. MeWo cells were used as a cell system for these studies 
because they can be infected in vitro and form syncytia that allow easy detection of 
infection-associated antigens. A syncytium is formed by fusion of a group of cells 
resulting in a shared and continuous cytoplasm and plasmamembrane and a ring of 
nuclei surrounding a concentration of Golgi bodies in the center of the syncytium 
(49),(50).  
MeWo cells were seeded in the ratio of 1 infected cell per 50 uninfected cells and 
infection was allowed to proceed for 48 hours. Then the cells were fixed by 2% 
formaldehyde and permeabilized using 0.5% Triton-X 100 in PBS. Subsequently, the 
cells were incubated with ORF specific primary antibodies. The primary antibodies 
were detected by incubation with secondary Alexa 488-conjugating goat anti-mouse 
antibodies. Epifluorescence microscopy was used to detect whether the antibodies 
tested gave a specific signal and if yes, where in the infected cell the respective VZV 
protein was detected. With this approach antibody producing clones against VZV 
proteins were screened, detected and studied in VZV infected MeWo cells. In total, 
123 mother wells which were producing VZV antibodies were screened positive 
covering 52 VZV ORFs (Table 9). In average every VZV ORF was covered by 3 to 4 
different hybridoma clones. 
 
4.3.4 Comparison of influence of acetone and formaldehyde on fixation 
In order to determine whether the fixation / permeabilization agents affect the 
reactivity of the positive antibodies, we compared acetone and formaldehyde fixation. 
The affects of acetone and formaldehyde was tested on five different ORF specific 
antibodies (ORF4, ORF16, ORF62, ORF63, ORF66). Although an 
immunofluorescence signal was detected for all five antibodies using both fixation 
methods, a weaker signal was observed for the ORF62 and ORF63 antibodies upon 
use of acetone (Figure 16). So, for the subsequent immunofluorescence analysis, 
formaldehyde was generally used. 
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ORF 4 (FA) ORF 4 (Acetone)
ORF 16 (FA) ORF 16 (Acetone)
ORF 62 (FA) ORF 62 (Acetone)
ORF 63 (FA) ORF 63 (Acetone)
ORF 66 (FA) ORF 66 (Acetone)
 
 
Figure 16: Comparison of influence of fixation reagents in immunofluorescence analysis. 
Monolayers of uninfected MeWo cells mixed with pOKA infected MeWo cells at a ratio of 50:1 were 
seeded on glass slides. Two days post infection, cells were fixed with 3% formaldehyde and 
permeabilized by 0.5 % TritonX-100 (left side). Alternatively, cells were fixed with icecold acetone 
(right side). Indirect immunofluorescence was performed using ORF specific mouse monoclonal 
antibodies followed by Alexa 488-conjugated secondary goat-anti mouse antibodies. DNA was 
visualised by DAPI staining. Pictures were obtained using an epifluorescence microscope (Leica). The 
bar shown on the bottom right hand side of each picture corresponds to 250µm and the same 
magnification was maintained in all panels. The DAPI (blue) and fluorescence (green) pictures were 
merged using Leica software. 
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4.3.5 Cellular localisation of all VZV proteins 
In parallel to screening of positive hybridoma clones, subcellular localisation of the 
VZV proteins was studied using the same cell system. In order to obtain a general 
overview of the subcellular localisation of each protein, epifluorescence microscopy 
was applied. With this approach all VZV proteins could be clearly detected in 
numerous VZV infected single cells or syncytia. We have chosen to study the 
localisation separately in single cells and syncytia since changes in localisation of 
VZV proteins are expected to occur upon syncytial cell fusion and ongoing infection 
associated with formation of syncytia. Such a high-throughput localisation study in 
the context of VZV infection with ORF specific antibodies has not been attempted by 
any investigator sofar.  
According to the localisation observed, the proteins could be classified into three 
groups: 1) cytoplasmic localisation, 2) nuclear localisation or 3) both cytoplasmic and 
nuclear localization. In total, we have obtained localisation data for 52 ORFs (74%) in 
syncytia and for 50 ORFs (71%) in single cells. In VZV infected syncytial cells, 20 
ORFs were localised in the nucleus (38%), 16 ORFs were localised in the cytoplasm 
(31%) and 16 ORFs localised to both the nucleus and cytoplasm (31%). In VZV 
infected single cells, 18 ORFs were found in the nucleus (36%), 20 ORFs were 
located in the cytoplasm (40%) and 12 ORFs localised to both the nucleus and 
cytoplasm (24%). The summary of these results is presented in Figure 17, Figure 19 
and Table 7. The subcellular localisation of each individual VZV ORF is shown in 
detail in Table 8. The immunofluorescence pictures of three ORFs (ORF2, ORF39, 
and ORF53) were not included in the data. We conclude from our observation that 
the subcellular localisation of 9 VZV proteins (ORF3, ORF8, ORF9, ORF12, ORF21, 
ORF27, ORF32, ORF57, ORF58) were altered between syncytia and single cells. An 
exceptional localization was observed for ORF24 and its partner protein ORF27 
which both localised to the nuclear membrane in accordance with the localization of 
their orthologous proteins in HSV, CMV, EBV and KSHV. A picture obtained by 
confocal microscopy that shows the confinement of ORF24 to the nuclear periphery 
of syncytia is shown in Figure 18. 
Of the 70 VZV proteins we could visualise, subcellular localisation of 30 VZV ORFs 
was published previously, and there is an excellent correlation between our data and 
previous reports (Table 8). In contrast, the subcellular localisation of 3 VZV ORFs 
(ORF37, ORF60, ORFS/L) was not in agreement with published data as is shown in 
 61 
Table 8. The transmembrane glycoproteins ORF37 (gH) and ORF60 (gL) were 
published to localize to the ER, Golgi or to the plasmamembrane reflecting their 
biochemical properties and their association with the secretory pathway. Quite in 
contrast, the antibodies generated reacted with an antigen located to the nucleus. 
ORF10 and ORFS/L were previously reported to reside in the cytoplasm while we 
observed a nuclear signal. The reason for this discrepancy could be a mixup of 
samples, cross-reactivity of antibodies with an unrelated protein or less likely, sofar 
undetected properties of these proteins. Apart from these some minor differences 
were observed for ORF20 and ORF25. Both of these proteins were detected as 
cellular in our observation but other investigators have only found them in the 
cytoplasm.  
The localisation was also classified on the basis of different functions of proteins like 
structural and non-structural proteins. The structural proteins comprise glycoproteins, 
tegument and capsid proteins. The localisation of all VZV glycoproteins that were 
observed, were in excellent agreement with published data except for gH and gL as 
mentioned above. Six out of 8 tegument proteins could be localised. The subcellular 
localisation of 3 tegument proteins (ORF9, ORF21 and ORF65) coincided with 
studies of other researchers. ORF21 was found in the nucleus of single cells whereas 
in syncytia it was located to both the nucleus and cytoplasm. For 3 tegument proteins 
(ORF11, ORF12, and ORF22) no localisation was reported sofar and the localisation 
newly determined in this study is shown in Table 8. ORF22 is the largest tegument 
protein of the VZV proteome and found to localise to the cytoplasm. The subcellular 
localisation of 2 additional tegument proteins (ORF43 and ORF46) could not be 
observed by us and has also not been reported by anyone else. Two out of 4 capsid 
proteins (ORF20, ORF23, but not ORF40 and ORF41) could be localized by us. Both 
were found in the nucleus consistent with their function and previous reports. The 
scaffolding protein ORF33 localized similar to the capsid proteins ORF20 and 
ORF23. All transactivator proteins (ORF4, ORF61, ORF62, ORF63) except for 
ORF10 showed a localization consistent with previous data. 
 
Table 7: Subcellular localization of VZV proteins in syncytia and single cells 
Cell type Nucleus and cytoplasm Cytoplasm Nucleus 
syncytia 16 ORFs 16 ORFs 20 ORFs 
single cells 12 ORFs 20 ORFs 18 ORFs 
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a) Nuclear localization (Figure 17 cont.) 
ORF26
ORF6
ORF17 ORF24
ORF16
ORF37
ORF48 ORF55
ORF33.5ORF32
ORF29ORF27
ORF56
ORF23
ORF10
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ORF60
ORF64 ORFS/L
ORF61ORF58
 
 
b) Cytoplasmic localization (Figure 17 cont.) 
ORF5 ORF11ORF7
ORF14 ORF22
ORF31
ORF28
ORF49 ORF50
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ORF67ORF65 ORF68
 
 
c) Nuclear and cytoplasmic localization (Figure 17 cont.) 
ORF47
ORF3 ORF8ORF4
ORF9
ORF21
ORF12 ORF13
ORF20 ORF25
ORF44 ORF57
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ORF66
ORF62 ORF63ORF59
 
 
Figure 17: Subcellular localisation of VZV encoded proteins in syncytia. Localisation observed 
for ORF proteins in syncytia was categorized as nuclear (a), cytoplasmic (b), and both nuclear and 
cytoplasmic (c). Monolayers of uninfected MEWO cells mixed with pOKA infected MEWO cells at a 
ratio of 50:1 were seeded on glass slides. Two days post infection, cells were fixed with 3% 
formaldehyde and permeabilized using 0.5 % TritonX-100. Indirect immunofluorescence was 
performed using ORF specific mouse monoclonal antibodies followed Alexa 488-conjugated 
secondary goat-anti mouse antibodies. DNA was visualised by DAPI staining. Pictures were obtained 
using an epifluorescence microscope (Leica). The bar shown on the bottom right hand side of all 
pictures corresponds to 250µm and the same magnification was maintained in all panels. The DAPI 
(blue) and fluorescence (green) pictures were merged using Leica software.  
 
 
 
 
Figure 18: Subcellular localisation of VZV protein ORF24. 
Monolayers of uninfected MeWo cells mixed with pOKA infected MeWo cells at a ratio of 50:1 were 
seeded on glass slides. Two days post infection, cells were fixed with 3% formaldehyde and 
permeabilized by 0.5 % TritonX-100. Indirect immunofluorescence was performed using ORF24 
specific mouse monoclonal antibodies followed by Alexa 488-conjugated secondary goat-anti mouse 
antibodies. DNA was visualised by DAPI staining. Pictures were obtained using an confocal 
microscope (Leica). The DAPI (blue) and fluorescence (green) pictures were merged using Leica 
software. 
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a) Nuclear localisation (Figure 19 cont.) 
ORF8ORF6
ORF17
ORF16
ORF23
ORF24
ORF37
ORF55 ORF56 ORF60
ORF44
ORF21
ORF29 ORF33.5
ORF48
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ORFS/LORF64ORF61
 
 
b) Cytoplasmic localisation (Figure 19 cont.) 
ORF5ORF3 ORF7
ORF12ORF9 ORF11
ORF14 ORF22
ORF31
ORF28
ORF49 ORF50
 
 68 
ORF57 ORF67 ORF68
 
 
c) Nuclear and cytoplasmic localisation (Figure 19 cont.) 
ORF4 ORF20
ORF32 ORF47ORF27
ORF58
ORF66ORF63
ORF62
ORF13
ORF59
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Figure 19: Subcellular localisation of VZV encoded proteins in single cells. Localisation of 
individual ORF proteins was categorized as nuclear (a), cytoplasmic (b), and both nuclear and 
cytoplasmic (c). Monolayers of uninfected MeWo cells mixed with pOKA infected MeWo cells at a ratio 
of 50:1 were seeded on glass slides. Two days post infection, cells were fixed with 3% formaldehyde 
and permeabilized using 0.5 % TritonX-100. Indirect immunofluorescence was performed using ORF 
specific mouse monoclonal antibodies followed by Alexa 488-conjugated secondary goat-anti mouse 
antibodies. DNA was visualised by DAPI staining. Pictures were obtained using an epifluorescence 
microscope (Leica). The bar shown on the bottom right hand side of all pictures corresponds to 250 
µm and the same magnification was maintained in all panels. The DAPI (blue) and fluorescence 
(green) pictures were merged using Leica software. 
 
Table 8: Subcellular localisation of VZV proteins in single cells or syncytia 
ORF No MW 
(kDa) 
calc 
MW 
This 
work 
Localization 
(Ref) 
Localization 
(this work) 
function HSV 
orthol 
locali  
Ref. 
single sync. 
ORF1 14.3 10 C  
(51)
   Membrane protein  
ORF2 31.4 32  C C Immediate early  
ORF3 23.6 24  C N&C hypothetical  
ORF4 59.5 60 N&C  
(52)
 N&C N&C Transactivator N (53) 
ORF5 44.8 45 C  
(54,55)
 C C Glycoprotein K  
ORF6 142.3 120  N N DNA-helicase-
Primase compleax 
C 
(53)
 
ORF7 34.1 34  C C Virion 
phosphoprotein 
N&C 
(53)
 
ORF8 52.1 52  N N&C dUTPase N&C 
(53)
 
ORF9 39.8 45/40 C  
(56)
 C N&C Tegument protein C 
(53)
 
ORF9a 11.6     Hypothetical (MP) C 
(53)
 
ORF10 54.0 54   N Transactivator N&C 
(53)
 
ORF11 107.7 108  C C Tegument protein / 
Transactivator 
 
ORF12 87.0 70  C N&C Tegument protein  
ORF13 39.7 40   N&C Thymidilate 
syntethase 
 
ORF14 73.7 65 C  
(57)
 C C Glycoprotein C  
ORF15 53.4     Membrane protein N&C 
(53)
 
ORF16 53.7 50  N N DNA-polymerase-
associated protein 
N 
(53)
 
ORF17 59.9   N N Host’’shutoff’’ protein  
ORF18 40.3 35    Ribonucleotide 
reductase (small SU) 
C 
(53)
 
ORF19 101.8 90  C C Ribonucleotide 
reductase (large SU) 
 
ORF20 63.5 55 C 
(58)
 N&C N&C Capsid protein N (53) 
ORF21 136.4 120 N&C  
(59,60,61)
 N N&C Tegument protein C 
(53)
 
ORF22 360.3 360  C C Tegument protein C 
ORF23 31.0 38 N  
(58,62)
 N N Capsid protein N&C (53) 
ORF24 35.5 36  N N Membrane 
associated 
phosphoprotein 
 
ORF25 20.6 21 C  
(63)
  N&C DNA packaging 
protein 
N&C 
(53)
 
ORF26 76.9 77   N Virion protein C (53) 
ORF27 43.9 44  N&C N Hypothetical protein N&C (53) 
ORF28 156.9 120  C C DNA polymerase N&C (53) 
ORF29 158.2 158 N  
(59,62,64)
 N N SS-DNA binding 
protein 
N&C 
(53)
 
ORF30 101.2  N&C  
(65)
   Virion protein  
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ORF31 114.1 114 C  
(66,57,67)
 C C Glycoprotein B C 
ORF32 18.9 30  N&C N Hypothetical protein  
ORF33.5 79.6 80 N  
(58)
 N N Protease N (53) 
ORF34 76.2     Virion protein N&C 
(53)
 
ORF35 34.0     Virion protein N 
(53)
 
ORF36 44.9 35    TK  
ORF37 110.6 111 C  
(66,57)
 N N Glycoprotein H C 
ORF38 71.2     Virion protein N&C 
(53)
 
ORF39 31.6 32 C  
(54)
 C C Membrane protein  
ORF40 183.4 140 C  
(58)
   Major capsid protein C 
(53)
 
ORF41 41.6 40 C 
(58)
    Capsid protein N&C 
(53)
 
ORF42 42.3 55    Not known  
ORF43 88.9     Tegument protein  
ORF44 47.8 45  N N&C Virion protein N&C 
(53)
 
ORF45 46.9  C  
(65)
   DNA packaging 
protein 
 
ORF46 26.3 35    Minor tegument 
protein 
N&C 
(53)
 
ORF47 67.1 55 C  
(68,69)
 N&C N&C S/T kinase C (53) 
ORF48 72.5 74  N N Deoxyribonuclease C (53) 
ORF49 10.8 10 C  
(70)
 C C Myristylated virion 
protein 
 
ORF50 57.2 52 C  
(71)
 C C Glycoprotein M C (72) 
ORF51 109.8 110    Origin binding 
protein 
 
ORF52 101.4 35    DNA helicase-
primase-complex 
 
ORF53 43.6 44  C C Hypothetical  
ORF54 101.1 98    Virion protein  
ORF55 115.8   N N DNA helicase-
primase-complex 
 
ORF56 32.2 32  N N Virion protein C (53) 
ORF57 9.5 10  C N&C Hypothetical  
ORF58 29.2 35  N&C N Nuclear 
phosphoprotein 
N 
(53)
 
ORF59 40.2 40  N&C N&C Uracil DNA 
glycosylase 
 
ORF60 21.0 18 C  
(57,67)
 N N Glycoprotein L C (73,74) 
ORF61 61.4 60 N  
(62,61)
 N N Transactivator  
ORF62 172.1 172 N&C  
(68,56,52,62)
 N&C N&C Major transactivator  
ORF63 36.6 37 N&C  
(75,62,61)
 N&C N&C Co-Transactivator N (53) 
ORF64 23.8   N N Virion protein N&C (53) 
ORF65 13.5 14 C  
(66,76)
 C C Tegument 
Phosphoprotein 
C 
(53)
 
ORF66 51.7 52 N&C 
(77)
 N&C N&C S/T kinase N&C (53) 
ORF67 46.6 50 C  
(78,79)
 C C Glycoprotein I N&C (53) 
ORF68 81.9 82 C  
(66,62,79)
 C C Glycoprotein E N&C (53) 
ORFS/L 21.0 18/20 C  
(80)
 N N Cytoplasmic protein  
 
4.3.6 Subcloning of positively screened hybridoma clones in WB and IF 
Approximately 1500 mother clones were initially tested positive by ELISA and of 
these, 218 were found reactive with VZV specific proteins. A greater number of VZV 
specific antibodies secreted by mother clones were positive in Western blotting than 
in indirect immunofluorescence. In total, an average of 3 to 4 positive clones was 
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identified specific for an individual VZV ORFs. For some ORFs the screening is still 
incomplete because either only Western blotting or indirect immunofluorescence was 
performed, the status of the screening is described in Table 9.  
The positively screened antibody secreting mother clones had to be subcloned. The 
purpose of subcloning is to isolate a specific hybridoma cell line that is clonally 
expanded and produces only a single kind of epitope specific antibody. For 
subcloning, positively screened mother wells were seeded in serial dilutions into 96 
well plates at the ratio of 0.3 cells / well. After cultivation, the subclones that were 
producing only one ORF specific VZV antibody were screened again by Western 
blotting and indirect immunofluorescence. So far, clones derived of 218 mother 
clones (14%) covering 61 VZV proteins were re-isolated. Of these 218 clones, 190 
clones were found to be positive in Western blotting while 123 clones were identified 
to be positive in immunofluorescence (Table 9).  
69 VZV proteins
314 fusions
>1600  positive
motherwells
immunisation of >65 
proteins and 5 peptides 
218 mABs against
61 proteins
 
 
Figure 20: Summary of screening VZV-specific antibodies produced by hybridoma clones. 
The figure shows status of the current project at different steps. It explains nearly 65 proteins were 
immunised and 314 fusions were made successfully. So far, 1600 positive motherwells were screened 
by ELISA and from this 218 hybridoma clones producing antibodies to 61 VZV ORF’s were tested 
positive. 
 
Table 9: List of all mother wells screened positively in WB and IF 
ORF MW subclones WB IF 
     
Orf2 1G12  pos  pos 
 4G11 2_1 pos  pos 
  2_2 pos  NT 
 7H2  pos  pos 
     
Orf3 3B10 3_1 pos pos 
 3B10 3_2 pos pos 
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Orf4 3B6 4_2 pos pos 
 -//- 4_5 pos pos 
 -//- 4_4 pos pos 
 2F7  pos neg 
     
Orf5 6A6  neg pos 
 7E5  pos  pos 
 1C12  pos neg 
 5A6  pos  pos 
 5B6  nt pos 
 6B11  pos  pos 
 7F4  pos  pos 
 -//- 5_12 pos neg 
 -//- 5_13 pos neg 
 8E5  pos  NT 
 8C4  pos  NT 
 6A9  pos  NT 
 1H2  pos  NT 
 3H7  pos  NT 
 2H11  pos  NT 
     
Orf6N -//- 6N_01 pos  neg 
 -//- 6N_02 pos  neg 
 7B9  neg pos 
     
Orf7 1H11 7_1 weakly pos pos 
 -//- 7_2 weakly pos pos 
 2F2 7_3 pos pos 
 2F2 7_4 pos pos 
 3D6 7_5 pos pos 
 -//- 7_6 pos pos 
 4F9 7_7 pos pos 
 -//- 7_8 neg pos 
     
Orf8 6A10 8_1 pos pos 
 -//- 8_2 pos pos 
 -//- 8_3 pos pos 
     
Orf9C 7B5  neg pos 
 3H4  neg pos 
 4A3  pos pos 
 1C7  pos neg 
 -//- 9C_11 pos NT 
 -//- 9C_12 pos NT 
 6H3  neg pos 
 -//- 9C_09 pos NT 
 -//- 9C_10 pos NT 
     
Orf10 1A4  pos NT 
 -//- 10_9 pos pos 
 1B9  weakly pos NT 
 2D4  pos NT 
 2H8  pos NT 
 -//- 10_12 pos pos 
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 -//- 10_13 pos NT 
 3E2  weakly pos pos 
 3F4  pos NT 
 3F5  weakly pos NT 
 3A12  pos pos 
 5F2  pos neg 
 5H3  pos NT 
 5H6  pos neg 
 5A8  pos neg 
 -//- 10_10 pos pos 
 -//- 10_11 pos pos 
 5D11  weakly pos NT 
 4G3  weakly pos NT 
 4A7  weakly pos NT 
     
Orf11N 1C3  pos NT 
 1E11  pos neg 
 -//- 11_04 pos NT 
 -//- 11_05 pos NT 
 3E2  pos NT 
 -//- 11_06 pos NT 
 -//- 11_07 pos NT 
 6A10  pos NT 
 6B11  pos NT 
 8F5  pos NT 
 -//- 11_08 pos NT 
 1B6  pos NT 
 1D9  pos NT 
 -//- 11_03 pos NT 
 5E9  pos pos 
 7A2  pos weakly pos 
 7C11  pos pos 
 8F8  pos NT 
 8B11  pos pos 
 4B11  pos  
     
Orf 12 1E10 12_3 pos pos 
 -//- 12_4 pos pos 
     
Orf 13 3G4 13_8 neg pos 
 2B9 13_10 pos neg 
 -//- 13_11 pos neg 
     
Orf 14 4A12 14_1 pos pos 
 -//- 14_2 pos pos 
 -//- 14_3 pos pos 
 -//- 14_4 pos pos 
 -//- 14_5 pos weakly pos 
 2E7 14_6 pos pos 
 -//- 14_7 pos neg 
 -//- 14_9 pos weakly pos 
     
Orf 16 9C6 16_6 asc pos pos 
     
Orf17C 2G10  neg pos 
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 -//- 17C_7 NT pos 
 -//- 17C_8 NT pos 
     
Orf18C 3H6  pos  neg 
 -//- 18C_7 pos xreact 
 -//- 18C_8 pos neg 
 4A12  weakly pos neg 
 -//- 18C_9 pos xreact 
 -//- 18C_10 pos neg 
 5F1  pos  neg 
 -//- 18C_11 pos neg 
 6H2  pos  NT 
 -//- 18C_12 pos xreact 
 -//- 18C_13 pos pos 
 7F10  pos  NT 
     
Orf19N 4A11  pos  neg 
 -//- 19N_1 pos pos 
 -//- 19N_2 pos neg 
 -//- 19N_3 pos pos 
     
Orf20 1E2  pos neg 
 -//- 20_ 7 pos neg 
 -//- 20_ 8 pos neg 
 4D4  pos pos 
 7H5  pos pos 
 8F5  pos pos 
 -//- 20_09 pos pos 
 -//- 20_10 pos pos 
 1G7  pos pos/xreact 
 2H10  pos pos 
  20_13 pos pos 
  20_14 pos pos 
 8E_10  pos neg 
 -//- 20_11 pos neg 
 -//- 20_12 pos neg 
 7B4  pos pos 
 4A10  pos NT 
 6C5  NT pos 
     
Orf21_3 1C1 21_3_1 pos pos 
 -//- 21_3_2 pos neg 
     
Orf22_3 4C8 22_3_5 pos neg 
 -//- 22_3_6 pos neg 
 5A11 22_3_7 pos pos 
     
Orf23 7C12 23_1 neg pos 
 -//- 23_5 pos NT 
 6H8 23_2 pos pos 
 -//- 23_3 pos pos 
 8D7 23_6 pos NT 
     
Orf24 1E1 24_1 weakly pos pos 
 -//- 24_2 weakly pos pos 
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 -//- 24_3 weakly pos pos 
 1G11 24_4 pos pos 
 -//- 24_5 pos pos 
 -//- 24_6 pos pos 
 3B7 24_7 pos pos 
 -//- 24_8 pos pos 
 -//- 24_9 weakly pos pos 
 3G10 24_10 weakly pos pos 
 -//- 24_11 weakly pos weakly pos 
     
Orf25 1B12  pos  pos 
 -//- 25_10 pos neg 
 -//- 25_11 pos neg 
 5B11  pos  neg 
     
Orf26 1E6 26_1 neg pos 
 -//- rekl.26_5 weakly pos neg 
 -//- rekl.26_6 weakly pos neg 
 -//- 26_4 neg pos 
 1H12 26_2 pos neg 
     
Orf27 7A10  pos pos 
  27_1 pos pos 
  27_2 pos pos 
 4G3  pos pos 
  27_3 pos pos 
  27_4 pos pos 
 7H9  pos neg 
     
Orf28.1 1-E9  pos  pos 
     
Orf29.1 8C1  neg pos-xreaxt 
 5B4  neg pos-xreaxt 
     
Orf31 1C1    
 -//- 31C_1 pos pos 
 -//- 31C_2 pos pos 
 -//- 31C_5 pos pos 
 -//- 31C_6 pos pos 
 2A7 31C_7 pos pos 
 -//- 31C_8 pos pos 
     
Orf32 6E1 32_1 pos pos 
 -//- 32_2 pos pos 
 5E3 32_4 pos  neg 
     
Orf33, 33.5 4F1 33.5_1 pos pos 
 -//- 33.5_2 pos pos 
 -//- 33.5_3 pos pos 
     
Orf36 8B11  pos  pos 
 -//- 36_15 pos  NT 
 -//- 36_16 pos  neg 
 5C2  pos  neg 
 -//- 36_13 pos neg 
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 -//- 36_14 pos neg 
     
Orf37 3A11  pos pos 
  37_14 pos neg 
 2D12  pos neg 
 1H6  pos neg 
 1C6  pos pos 
  37_12 pos pos 
  37_13 pos pos 
 6A7  NT pos 
 3C10  NT pos 
 4F7  NT pos 
 1A4  NT pos 
 2E6  NT pos 
 7D3  neg pos 
 -//- 37N_9 neg pos 
 -//- 37N_10 neg pos 
 -//- 37N_11 neg pos 
     
Orf39N 3B3 39N_2 weakly pos pos 
 -//- 39N_7 weakly pos pos 
 3A8 39N_3 neg weakly pos 
 -//- 39N_4 pos neg 
 -//- 39N_5 pos weakly pos 
 -//- 39N_6 pos weakly pos 
 -//- 39N_8 weakly pos weakly pos 
     
Orf40.1 6H2  pos  neg 
 7F6  pos  neg 
     
Orf41 5F6 41_1 pos neg 
 -//- 41_2 pos neg 
 -//- 41_4 pos  neg 
 3G8  pos  neg 
 5F5  pos  neg 
 3F8  pos  neg 
 5E4  pos  neg 
 5F6  pos  neg 
 3A4  pos  neg 
 1F10  pos  neg 
 4B9  pos  neg 
     
Orf42 3E9  pos  neg 
 2F11  pos  neg 
     
Orf44N 1E6  pos pos 
 1C8  pos pos 
  44N_3 pos neg 
  44N_4 pos NT 
 2E9  pos neg 
 4G2  pos neg 
 4G11  pos neg 
 6G3(6B3)  pos NT 
 8D6  pos NT 
 3F1  pos NT 
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 4F7  pos NT 
 5B10  pos NT 
 2F4  pos NT 
  44N_1 pos neg 
  44N_2 pos pos 
 8C10  pos NT 
 6D3  pos NT 
     
Orf46 2C11  pos neg 
  46_9 pos neg 
  46_10 pos neg 
     
Orf47 6D12  pos pos 
 -//- 47_9 pos NT 
 -//- 47_10 pos NT 
 4E4  pos neg 
 7E11  pos neg 
 6A4  weakly pos NT 
 7B9  pos pos/xreact 
 6H8  pos pos/xreact 
 6B8  pos pos 
 -//- 47_1 pos NT 
 -//- 47_2 pos NT 
 2H8  pos pos 
 -//- 47_5 pos NT 
 -//- 47_6 pos NT 
 8C12  pos NT 
 7D6  pos pos 
 -//- 47_3 pos NT 
 -//- 47_4 pos NT 
 4C3  pos NT 
 -//- 47_7 pos NT 
 -//- 47_8 pos NT 
 8D8  pos NT 
     
Orf48 6H3 48_1 pos pos 
 -//- 48_2 pos pos 
 -//- 48_3 pos pos 
 -//- 48_4 pos pos 
 -//- 48_5 neg pos 
 -//- 48_7 neg pos 
 3E12 48_6 pos pos 
 -//- 48_8 pos pos 
 6G9 48_9 weakly pos pos 
 -//- 48_10 weakly pos pos 
 -//- 48_11 weakly pos pos 
 -//- 48_12 neg pos 
 -//- 48_15 neg pos 
 6G6 48_16 pos pos 
 -//- 48_17 NT pos 
     
Orf49 6B2 49_7 pos pos 
 -//- 49_8 pos pos 
 4G9  pos pos 
 3E9  pos pos 
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 6A4  pos neg 
 2E3  weakly pos neg 
 4G10  pos neg 
     
Orf50 3D7  pos pos 
     
Orf51 3G5  pos neg 
 6A11  pos NT 
     
Orf52N 2H12  pos neg 
 4F4  pos neg 
 1C2  pos neg 
 2G5  pos neg 
 5B5  pos neg 
 6H11  pos neg 
 5A9  pos neg 
 5D6  pos neg 
 3C3  pos NT 
     
Orf53 2C3  neg pos 
 -//- 53_10 pos neg 
 4F2  pos  neg 
 -//- 53_11 pos  neg 
 -//- 53_12 pos  neg 
     
Orf54 1B3 54_1 pos neg 
 -//- 54_2 pos neg 
 5G11  pos  NT 
 -//- 54_8 pos NT 
 -//- 54_9 pos NT 
     
Orf55 2F11 55_1 neg pos 
 -//- 55_2 neg pos 
 4B6 55_3 neg pos 
 -//- 55_4 neg pos 
     
Orf56 1B3 56_1 neg pos 
 -//- 56_2 neg pos 
 7D1 56_4 pos neg 
 9D7 56_5 neg pos 
 -//- 56_6 pos pos 
 10C2 56_7 pos pos 
 -//- 56_8 pos pos 
 10E7 56_9 neg pos 
 -//- 56_10 neg pos 
     
Orf57 6A2 57_3 neg pos 
 -//- 57_4 neg pos 
 8C4 57_7 pos pos 
 -//- 57_10 pos pos 
     
Orf58 9A2 58_1 pos pos 
 -//- 58_3 pos pos 
 -//- 58_4 neg pos 
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Orf59 10F11 59_1 pos pos 
 -//- 59_3 pos pos 
     
Orf60C 1H4 60C_1 neg pos 
 -//- 60C_2 neg pos 
 5E5 60C_5 pos neg 
 -//- 60C_6 pos neg 
     
Orf61 1G6 61_1 neg pos 
 -//- 61_2 pos pos 
 2H4 61_3 pos pos 
 -//- 61_4 neg pos 
     
Orf62 4D1 62_1 weakly pos pos 
 -//- 62_2 weakly pos pos 
 3A8 62_3 weakly pos pos 
 -//- 62_4 weakly pos pos 
 2D3 62_5 pos pos 
 -//- 62_8 pos neg 
 3B3 62_6 pos pos 
 -//- 62_7 pos pos 
     
Orf63 4B11 63_1 pos pos 
 -//- 63_2 pos pos 
 -//- 63_3 pos pos 
 -//- 63_4 neg pos 
 4C11 63_5 neg pos 
 4B11 63_6 neg pos 
 4C11 63_7 neg pos 
 -//- 63_8 pos pos 
 -//- 63_9 pos pos 
     
Orf64 5G10  neg pos 
 1D4  neg pos 
     
Orf65N 7B12  pos NT 
 7F12  pos pos 
     
Orf66 10H10 66_7 pos neg 
 2D7 66_8 pos pos 
 -//- 66_9 pos neg 
 -//- 66_10 neg pos 
     
Orf67 3D6 67C_1 pos pos 
 -//- 67C_2 pos pos 
 8A4 67C_3 neg pos 
 -//- 67C_4 neg pos 
 -//- 67C_5 neg pos 
 3D6 67C_6 pos pos 
     
Orf68 6B12 68_2 pos pos 
 -//- 68_3 pos pos 
 -//- 68_4 pos pos 
 3E2 68_5 pos neg 
 -//- 68_6 pos neg 
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S/L 4E3 SL_C_1 pos pos 
 -//- SL_C_2 pos pos 
 
 
4.4 Epitope Mapping by Pepscan 
The synthetic peptides for the VZV antigens used in the Pepscan analysis were 
deduced from nucleotide sequence data of pOKA VZV strain. To map the epitopes 
the respective antigen peptides (15-mers, overlapping by 12 aa spanning the entire 
or partial antigen sequences) were synthesized and coupled to continuous cellulose 
membranes. Subsequently, the cellulose membranes spotted with respective 
antigenic peptides were blocked and then incubated with specific hybridoma 
supernatants. After washing, the cellulose membranes were incubated with alkaline 
phosphatase-conjugated goat-anti mouse secondary antibodies. The 
immunodominant regions (epitope) were detected using the ECL detection system 
(Amersham-Pharmacia / GE Healthcare) and visualized using BIOMAX-MR 
autoradiography. 
 
4.4.1 Mapping of epitopes recognized on gK  
Two anti-gK mAbs from clone 6B11 and 5A6 were tested for identification of 
immunodominant regions. The anti-gK mAbs from clone 6B11 generated against 
glycoprotein K identified five discrete stretches of reactive peptides (Figure 21 a).  
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a) ORF5 / gK – clone 6B11 
MQALGIKTEHFIIMCLLS18GHAVFTLWYTAR31VKFEHECVYATTVINGGPVVWGS
YNNSLIYVTFVNHSTFLDGLSGYDYSCRENLLSGDTMVKTAIS96TPLHDKIRI106VL
GTRNCHAYFWCVQLKMIFFAWFVYGMYL135QFRRIR142RMFGPFRSSCELISP156T
SYSLNYVTRVISNILLGYPY178TKLARLLCDVSMRRDGMS195KVFNADPISFLYMH
K210GVTLLMLLEVIAHISSGCIVLLTLGVAYTPCALLYPTYIRILAWVVVCTLAIVELIS
YVRPKPTKDNHLNHINTGGIRGICTTCCATVMSGLAIKCFYIVIFAIAVVIFMHYEQR
VQVSLFGESENSQKH
1
3
2
4
8 109 11 14
5
12
6
7 13
15
1. LLSGHAVFTLWYTAR
2. GHAVFTLWYTARVKF
3. VKTAISTPLHDKIRI
4. AISTPLHDKIRIVLG
5. TPLHDKIRIVLGTRN
6. AWFVYGMYLQFRRIR
7. VYGMYLQFRRIRRMF
8. MYLQFRRIRRMFGPF
9. QFRRIRRMFGPFRSS
10. ISPTSYSLNYVTRVI
11. TSYSLNYVTRVISNI
12. YVTRVISNILLGYPY
13. RVISNILLGYPYTKL
14. SNILLGYPYTKLARL
15. KVFNADPISFLYMHK
 
Figure 21 (for legend see below)  
 
The residues in common between the different peptides were delimited by residues 
18GHAVFTLWYTAR31, 96TPLHDKIRI106, 135QFRRIR142, 
156TSYSLNYVTRVISNILLGYPY178, and 195KVFNADPISFLYMHK210. All of these five 
immunodominant peptides contain either arginine or isoleucine. MAbs derived of 
clone 5A6 also identified five different discrete stretches (Figure 21 b). The identified 
residues are 90VKTAISTPLHDKIRI106, 135QFRRIR142, 168SNILLGYPYTKL181, 
195KVFNADPISFLYMHK210, and 264LISYVRPKPTKDNHL279. All of these five 
immunodominant residues contain isoleucine. The immunodominant regions from 
135QFRRIR142 and 195KVFNADPISFLYMHK210 were reactive to two clones are very 
similar. 
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b) ORF5 / gK – clone 5A6 
MQALGIKTEHFIIMCLLSGHAVFTLWYTARVKFEHECVYATTVINGGPVVWGSYN
NSLIYVTFVNHSTFLDGLSGYDYSCRENLLSGDTM90VKTAISTPLHDKIRI106VLGT
RNCHAYFWCVQLKMIFFAWFVYGMYL135QFRRIR142RMFGPFRSSCELISPTSYSLN
YVTRVI168SNILLGYPYTKL181ARLLCDVSMRRDGMS195KVFNADPISFLYMHK210
GVTLLMLLEVIAHISSGCIVLLTLGVAYTPCALLYPTYIRILAWVVVCTLAIVE264LIS
YVRPKPTKDNHL279NHINTGGIRGICTTCCATVMSGLAIKCFYIVIFAIAVVIFMHYE
QRVQVSLFGESENSQKH
1
2 3 4
7
6
5
8
1. VKTAISTPLHDKIRI
2. AWFVYGMYLQFRRIR
3. VYGMYLQFRRIRRMF
4. MYLQFRRIRRMFGPF
5. QFRRIRRMFGPFRSS
6. RVISNILLGYPYTKL
7. SNILLGYPYTKLARL
8. KVFNADPISFLYMHK
9. LISYVRPKPTKDNHL
9
 
 
Figure 21: Epitope mapping of monoclonal antibodies to gK. Synthetic peptides covering the 
complete sequence of gK were coupled to cellulose membranes as 15 mers overlapping by 12 aa. 
The blocked membrane was incubated with the mAbs (a) clone 6B11 or (b) clone 5A6 of gK, followed 
by addition of secondary goat anti-mouse antibodies conjugated to alkaline phosphatase. The 
membrane was detected using ECL and developed by BIOMAX-MR autoradiography. Five discrete 
peptide stretches were recognised by mAb clones 6B11 and 5A6, and residues that were important for 
binding within the reactive peptide sequences are marked in bold. The localisation of the reactive 
peptide streches is shown on the bottom in the primary sequence of gK. 
 
4.4.2 Mapping of epitopes recognized on ORF24 
The clones 1G11 and 3B7 were raised against the N-terminal ORF24 fusion protein 
comprising residues 1 to 245. So, for screening purposes ORF24 peptides (15-mers, 
overlapping by 12 aa spanning residues 1 - 245) coupled to cellulose membrane 
were selected to map the epitopes. The mAb 1G11 detected seven discrete stretches 
of reactive peptides (Figure 22 a). The five residues in common between the different 
peptides were delimited by the residues 15GDNLLQRIR25, 93VLFQGF100, 135IKR139, 
168MGPEDPSRTIKL180, and 195NLDEYIRWR205. Two stretches 
144RPLQALMWVNCF156 and  157VRMPYVQLSFRF168 represented single reactive 
peptides. The mAb 3B7 identified three spots and these spots correspond to peptides 
9ERRRGCGDNLLQRIR25, 153NCFVRMPYVQLSFRF169, and 
189YKETGNNLDEYIRWR205  (Figure 22 b). Three epitopes recognized by antibodies 
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produced by clone 3B7 (153NCFVRMPYVQLSFRF169, 15GDNLLQRIR25, and 
195NLDEYIRWR205) showed also reactivity with clone 1G11 suggesting they are 
immunologically active. 
 
a) ORF24 – clone 1G11 
MSRRTYVRSERRRGC15GDNLLQRIR25LVVPSALQCCDGDLPIFDPQRPPARCV
FQFNGEDNVSEAFPVEYIMRLMANWAQVDCDPYIKIQNTGVS93VLFQGF100FF
RPTNAPVAEVSIDSNNVILSSTLSTGINLSALES135IKR139GGGIDR144RPLQALM
WVNCF156VRMPYVQLSFRF168MGPEDPSRTIKL180MARATDAYMYKETGN195
NLDEYIRWR205PSFRSPPENGSPNTSVQMQSDIKPALPDTQTTRV 
1. ERRRGCGDNLLQRIR
2. RGCGDNLLQRIRLVV
3. GDNLLQRIRLVVPSA
4. IKIQNTGVSVLFQGF
5. QNTGVSVLFQGFFFR
6. GVSVLFQGFFFRPTN
7. VLFQGFFFRPTNAPV
8. LSTGINLSALESIKR
9. GINLSALESIKRGGG
10. LSALESIKRGGGIDR
11. LESIKRGGGIDRRPL
12. IKRGGGIDRRPLQAL
13. RPLQALMWVNCFVRM
14. NCFVRMPYVQLSFRF
15. FRFMGPEDPSRTIKL
16. MGPEDPSRTIKLMAR
17. YKETGNNLDEYIRWR
18. TGNNLDEYIRWRPSF
20. NLDEYIRWRPSFRSP 
4 65 7 8
109 11
1918
14 15
12
16 1713
1 2 3
 
 
b) ORF24 – clone 3B7 
MSRRTYVRS9ERRRGCGDNLLQRIR25LVVPSALQCCDGDLPIFDPQRPPARCVF
QFNGEDNVSEAFPVEYIMRLMANWAQVDCDPYIKIQNTGVSVLFQGFFFRPTN
APVAEVSIDSNNVILSSTLSTGINLSALESIKRGGGIDRRPLQALMWV153NCFVR
MPYVQLSFRF169MGPEDPSRTIKLMARATDAYM189YKETGNNLDEYIRWR205P
SFRSPPENGSPNTSVQMQSDIKPALPDTQTTRV 
1
32
1. 9ERRRGCGDNLLQRIR25
2. 153NCFVRMPYVQLSFRF169
3. 189YKETGNNLDEYIRWR205
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Figure 22: Epitope mapping of monoclonal antibodies to ORF24. The overall reactivity of two anti-
ORF24 antibodies from two different clones 1G11 (a) and 3B7 (b) with peptides spanning the N-
terminal ORF24 sequence from residues 1 to 245 (15-mers, overlapping by 12aa) was tested. 
Cellulose membranes with spotted peptides were blocked and subsequently incubated with the mAbs 
1G11 and 3B7 reactive with ORF24, followed by addition of goat anti-mouse secondary antibodies 
conjugated to alkaline phosphatase and developed as described in Figure 19. The sequence 
corresponding to the numbers adjacent to the reactive spots are highlighted in the primary aminoacid 
sequence of ORF24 shown on the bottom.  
 
4.4.3 Mapping of epitopes recognized on gB 
To determine the epitopes clone 2A7 recognized on gB, a cellulose membrane with 
15-mer peptides with 12 aminoacid overlap spanning gB residues 750 to 869 was 
prepared. A single linear stretch of 30 residues within the carboxy-terminal part of gB 
was shown to bind clone 2A7 antibodies and is depicted in Figure 23 a.  
 
4.4.4 Mapping of epitopes recognized on gL 
To identify epitopes on gL recognized by clone 5E5 a cellulose membrane with 15-
mer peptides with 12 amino acids overlaps spanning aminoacids 29 to 160 was 
generated. A single linear stretch of 33 residues within the carboxy-terminal part of 
gL reacted with clone 5E5 antibodies (Figure 23 b).  
 
4.4.5 Mapping of epitopes recognized on gI 
The mAbs 3D6 were raised against a C-terminal gI fusion protein comprising 294 to 
355 aa. For epitope mapping, gI peptides (15-mers, overlapping by 12 aa spanning 
residues 294 to 355) were coupled to cellulose membranes and tested for antibody 
binding. Three discrete stretches were recognised by clone 3D6 antibodies as shown 
in Figure 23 c. IYR is a common region shared by all peptides. 
 
a) ORF31 / gB – clone 2A7 
KTSPMKALYPLTTKGLKQLPEGMDPFAEKPNATDTPIEEIGDSQNTEPSVNSGFDPD
KFREAQEMIKYMTLVSAAERQESK831ARKKNKTSALLTSRLTGLALRNRRGYSRV
R862TENVTGV
1 432 65
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b) ORF60 / gL – clone 5E5 
PLSDVSLIITEPCVSSVYEAWDYAAPPVSNLSEALSGIVVKT77KCPVPEVILWFKDKQ
MAYWTNPYVTLKGLAQSV111GEEHKSGDIRDALLDALSGVWVDSTPSSTNIPENGCV
WGADRLFQRVCQ
1 432 65
7
 
 
c) ORF67 / gI – clone 3D6 
3. RIKKHPIYRPNTKTR
4. KHPIYRPNTKTRRGI
5. IYRPNTKTRRGIQNA
294ISVKRRRIKKHPIYRPNTKTR316RGIQNA321TPESDVMLEAAIAQLATIREESPP
HSVVNP352FVK 
6 987 10
1 432
5
6.TPESDVMLEAAIAQLATIREESPPHSVVNP
1. ISVKRRRIKKHPIYR
 
 
Figure 23: Epitope mapping of monoclonal antibodies to ORFs 31, 60, and 67. For epitope 
mapping, pepscan cellulose membranes were spotted with peptides (13-mers, 12 overlapping amino 
acids) covering the C-terminal sequence of gB (residues 750 to 869), gL (residues 29 to 160) and gI 
(residues 294 to 355). The membranes were incubated with antibodies of clone 2A7 produced to gB 
(a), clone 5E5 produced to gL (b) and clone 3D6 produced to gI (c), followed by addition of goat anti-
mouse secondary antibodies conjugated with alkaline phosphatase. The membrane was developed as 
described in Figure 19. The epitopes recognized within gB, gL or gI are marked schematically. 
 
 
4.4.6 Mapping of epitopes recognized on gE 
For epitope mapping, antibodies produced by clone 6B12 were tested for reactivity 
on cellulose membranes spotted with 15-mer peptides harbouring a 12 amino acid 
overlap spanning gE residues 560 to 624. Eight peptide stretches were recognised 
by the specific antibodies (Figure 24). Peptide 282PGVLKVLRTEKQYLG298 is the 
common epitope region recognised by reactive spots 5 and 6. 
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ORF68 / gE – clone 6B12 
1
2 3
4
5 6
7
8
9 10 11
12
MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYY
HSDHAESSWVNRGESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGI
DSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDRHKIVNVDQRQYGDVFKGDL
NPKPQGQRLIEVSVEENHPFT183LRAPIQRIY193GVRYTETWSFLPSLTCTGDAAP
AIQHICLKHTTCFQDVVVDVDCAENTKED243QLAEISYRFQGKKEA259DQPWIV
VNTSTLFDELEL276DPPEIEPGVLKVLRTEKQYLG298VYIWNMRGSDGTSTYATF
LVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVF351SVGDTFSLAMHLQY
K367IHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPH
LAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSG
LYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPV528
NPGTSPLLRYAAWTG544GLAAVVLLCLVIFLICTAKRMRVK567AYRVDKSPY577
NQSMYYAGLPVDDFEDSESTDTEEEFGNAIGG608SHGGSSYTVYIDKTR624
1. ENHPFTLRAPIQRIY
2. PFTLRAPIQRIYGVR
3. LRAPIQRIYGVRYTE
4. QLAEISYRFQGKKEA
5. DPPEIEPGVLKVLRT
6. PGVLKVLRTEKQYLG
7. SVGDTFSLAMHLQYK
8. NPGTSPLLRYAAWTG
9. KRMRVKAYRVDKSPY
10. RVKAYRVDKSPYNQS
11. AYRVDKSPYNQSMYY
12. SHGGSSYTVYIDKTR
 
 
Figure 24: Epitope mapping of monoclonal antibodies to ORF68. The complete sequence of gE 
was coupled to cellulose membrane as synthetic peptides of 15mers overlapping by 12 residues. The 
membrane was incubated with the antibodies produced by clone 6B12 followed by addition of goat 
anti-mouse secondary antibodies conjugated with alkaline phosphatase. The membrane was 
developed as described in Figure 19. Five discrete peptide stretches were recognised by clone 6B12, 
and residues that were important for binding within the reactive peptide sequences are shown in bold. 
The localisation of the reactive peptide streche is shown on the bottom in the primary sequence of gE. 
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5. Discussion 
 
Varicella zoster virus causes chicken pox as primary infection which upon 
reactivation results in herpes zoster. VZV is of high clinical relevance due to the high 
prevalence of Varicella zoster in humans, its highly contagious nature and a high 
morbidity rate associated with reactivation. Despite of this, many aspects of the 
infection cycle, of latency and reactivation are not well understood. Moreover, the 
function of many individual proteins specific to VZV is poorly characterized. Until 
today, research is hampered by the lack of cell-free virus and effective animal models 
restricting analysis to in vitro cell culture using cell-associated non-synchronized 
virus.  
Like all herpesviruses, VZV are large viruses that exhibit complex biological 
mechanisms to proliferate efficiently. This is simply exemplified by the association of 
a large number of viral proteins to form new viral particles. In the course of infection, 
herpes virus proteins however do not only interact with each other but also with a 
large number of host proteins. To analyse and understand these complex 
mechanisms, systems biology approaches represent a powerful tool. So far, genome 
wide interactions of five different herpesviruses, comprising all subfamilies of human 
herpesviruses (HSV, VZV, EBV, CMV, KSHV) were studied using yeast-two-hybrid 
(Y2H) ((81,82)). However the Y2H does not provide a means to understand and study 
fundamental aspects of viral morphogenesis in the viral or cellular context. To 
systematically detect and characterize all VZV expressed proteins in the course of 
infection we generated a comprehensive antibody collection. To our knowledge this is 
the first approach to generate an ORFeome-wide antibody collection. With certainty, 
this collection will reveal many so far uncovered biological aspects of VZV infection 
and will be highly welcomed by the VZV research community. 
 
5.1 Pipeline for high-throughput generation of antibodies against the VZV 
proteome 
As a permanent source of antibodies for future studies, we chose to produce 
monoclonal antibodies in mice using the conventional hybridoma technology. To 
generate VZV proteins for immunization we implemented some strategies to increase 
the efficiency in a limited time. For cloning a VZV entry library and subcloning it into 
different expression vectors we have chosen the Gateway® technology from 
 88 
Invitrogen because it is rapid, robust, cost-efficient and highly amenable to high-
throughput systems. By using the recombinational Gateway® technology we have 
cloned all 70 open reading frames of VZV without stop codon, and thus constructed a 
VZV entry library ((32)). The Gateway®  technology gives flexibility to subclone the 
entry clones into different Gateway® compatible vectors, for eg. into a variety of 
expression vectors with different tags for protein expression and purification in 
bacteria. So, to maximise our chance of protein expression and purification we have 
cloned the entry library into four different pET derived expression vectors containing 
four different tags like N-terminal His6, C-terminal His6, N-terminal MBP, or N-
terminal GST tag. Far beyond, this entry library can be transferred into any 
compatible vector allowing expression in various cellular systems like yeast, insect or 
mammalian cells.  
The vast majority of VZV proteins used for immunization was produced by bacterial 
expression and subsequent protein purification as this system is economical, fast and 
requires minimal technical expertise to establish a laboratory protein production 
system (83). Proteins that could not be obtained using the bacterial expression system 
were produced using the baculovirus-driven expression in infected insect cells. 
Moreover, synthetic peptides were generated for several proteins that were not 
obtained by either system.  
Purified proteins and synthetic peptides were immunised to mice and screened 
initially in ELISA for positive mABs. To screen a large number of clones a high-
throughput 96 well ELISA platform was established. To this end, ELISA plates were 
coated with bacterially expressed and purified VZV proteins to screen hybridoma 
mother clones for production of VZV specific antibodies. Antibodies giving positive 
signals on the immunogen using ELISA were subsequently tested by Western 
blotting (WB) on VZV infected cell material. This enabled us to determine whether a 
specific antibody recognized a protein of the correct molecular weight in lysates of 
VZV infected but not of uninfected MeWo cells. The same antibodies were then 
tested by indirect immunofluorescence to determine the subcellular localization of the 
VZV encoded protein in infected cells again in comparison to uninfected cells. 
Altogether the second part of screening in the virus context resulted in a collection of 
faithfully tested antibodies that can be used for various studies of specific VZV 
encoded proteins.  
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5.2 Limitations of the pipeline 
In the process of generating antibodies we have encountered several limitations at 
every step while implementing our strategies. Problems occurred at various steps like 
PCR amplication of large DNA fragments and cloning into the entry vector. Large 
DNA sequences of more than 4000kb were difficult to amplify due to premature chain 
termination, or frame shifts and stop codons were introduced randomly because of 
high mutation rates. So, ORF21, ORF22, ORF28 and ORF29 were amplified as 
smaller fragments. To facilitate purification of certain VZV ORFs, proteins predicted 
to contain transmembrane regions were cloned as soluble domains lacking the 
transmembrane domains. We have also generated small fragments for ORFs where 
a full length protein showed poor expression in bacteria. 
Several VZV proteins gave difficulties during expression / purification using the 
bacterial system. If fragmentation did not solve the problem, the baculovirus 
expression system was applied. This system facilitates high levels of protein 
expression, posttranslational modifications, such as protein N-glycosylation (similar to 
mammalian cells) and easy to grow insect cells in large amounts ((84,85,86)). If all 
expression systems were exhausted, synthetic peptides were ordered.  
Due to poor expression of VZV proteins, the concentration of protein used for 
immunization was low resulting in few positive hybridoma clones. A second problem 
arose during ELISA testing. Low amounts of specific protein available for coating of 
ELISA plates led to problems in discriminating positive antibody producing clones 
from negative clones. Moreover, we observed cross-reactivity. Many clones that were 
screened positive by ELISA were detected negative in Western blotting and / or IF. 
Many false positive clones were also obtained because of low specificity and high 
background in ELISA. Cross-reactive clones were produced by the addition of a 50 
amino acid sequence which was encoded by the linker region up to a late occurring 
Stop codon in the Gateway®  vector resulting in a general C-terminal extension of 
the protein of interest. Due to the generation of antibodies against this C-terminally 
encoded Gateway® vector sequence many clones initially tested positive by ELISA 
turned out negative when tested on VZV infected cells. To overcome this problem a 
control protein carrying this same 50 aminoacid extension was used for ELISA 
screening. Moreover, for some of the VZV proteins we could not generate antibody 
producing positive clones. These proteins might be poorly immunogenic. Finally, we 
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have observed that several clones producing monoclonal antibodies specific to VZV 
proteins also exhibit cross-reactivity with host proteins. 
 
5.3 Potentiality of the Antibody Collection 
To our knowledge this is the first time, antibodies were generated against the whole 
genome of such a complex virus. This will enable the comprehensive analysis of all 
VZV encoded proteins in the virus context. So far, our antibody clone collection 
contains 218 mother clones producing antibodies to 61 VZV proteins (87%). In 
average, each VZV ORF is covered by 3 to 4 positive clones, however depending on 
the ORF varying between one to 10 different clones. In total, 190 clones were 
identified as positive in Western blotting covering 57 ORFs (81%). In 
immunofluorescence 123 antibodies were tested positive covering 52 VZV ORFs 
74%). To our surprise 50 VZV ORFs (71%) could be detected both by WB and IF, 
two methods that vary in conserving protein conformation (Figure 25). While 
screening the antibodies with IF gives a specific subcellular signal WB allows 
detection of the molecular weight of the protein in question, providing an intrinsic 
control due to detection of the molecular weight. Thus, the fact that 50 ORFs (71%) 
are detected by specific antibodies using both of these methods underscores the 
validity and high fidelity of our collection. Moreover, a selection of these antibodies 
tested under altered IF conditions indicate that many antibodies are tolerant to 
sample preparation and thus should be widely applicable in using various methods 
including immunocytochemistry, immunoelectronmicroscopy or immunoprecipitation.  
More than 83% (47 of 57) of the antibodies that were screened positive in WB 
recognised a VZV protein of the predicted molecular weight. Nearly 17% (10 
proteins) of the VZV proteins migrated aberrantly in SDS-PAGE possibly due to 
protein truncation, proteolytic processing, or to a highly basic or acidic nature. In IF all 
the proteins showed the expected localisation in comparison to their herpesviral 
conserved and predicted function. Future studies aim at detailed analysis of those 
antibodies where detection of the 10 remaining ORFs by WB was unsatisfactory. 
Sofar, antibodies for 9 VZV ORFs were not generated and the process of production 
of antibodies recognizing these ORFs is ongoing.  
In summary, our collection of antibodies allows detection of VZV proteins in absence 
of a protein tag either in situ, under native or denatured conditions, in the viral context 
but also under ectopic expression in any cell system. Moreover, since many ORFs 
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are covered by several different monoclonal antibodies we expect that this collection 
also enables the discrimination of splice and modification variants thus potentially 
giving many novel insights into VZV replication. 
 
Immunofluorescence Western Blot
5052 57 
 
 
Figure 25: Status of hybridoma clones reactive in WB and IF for VZV ORFs. The picture indicates 
how many VZV ORFs are positively recognized by hybridoma secreted antibodies in WB and IF. In 
total, 52 VZV ORFs were recognized in IF, 57 in WB and 50 in both WB and IF. 
 
5.4 Intracellular localisation of VZV proteins 
Localization of VZV proteins in the viral context was part of the screening procedure. 
At the same time a nearly comprehensive analysis of the subcellular localization of 
52 (74%) VZV proteins - 22 of them for the first time - was achieved. To our 
knowledge, the intracellular localisation of only 30 VZV encoded proteins - however 
not always in the viral context - was previously investigated and published. 
Localisation was studied both in syncytia and single cells to understand the 
complexity and dynamics of VZV infection. So far, we have obtained localisation for 
52 (74%) proteins in syncytia and for 50 (71%) proteins in single cells. In VZV 
infected syncytial cells 20 ORFs were localised to the nucleus (38%), 16 ORFs were 
localised in the cytoplasm (31%) and localisation of 16 ORFs was observed in both 
nucleus and cytoplasm (31%). For proteins observed in VZV infected single cells 18 
were nuclear (36%), 20 in the cytoplasm (40%) and 12 ORFs were distributed 
throughout the cell (24%). The subcellular localisation of four ORFs (ORF2, ORF19, 
ORF39, and ORF53) was not included in the thesis but observed by us. For nine VZV 
encoded proteins, ORF3, ORF8, ORF9, ORF12, ORF21, ORF27, ORF32, ORF57, 
ORF58 (17%), subcellular localisation was altered when comparing single cells and 
syncytia. This difference in subcellular localisation could indicate that during infection 
VZV exhibits different dynamics in syncytia and single cells. 
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Figure 26: Intracellular localisation status of VZV proteins in single cells and syncytia. The 
figure indicates how many VZV proteins were found in the nucleus, in the cytoplasm, both nucleus and 
cytoplasm in syncytia and single cells using hybridoma produced antibodies. 
 
The nuclear preponderance of VZV encoded proteins is in good agreement with the 
viral lifecycle, which is preferentially associated with the nucleus. In syncytial cells, 18 
VZV proteins (35%) localised to the nucleus. To gain insight into their mode of 
subcellular trafficking, we analysed whether nuclear VZV proteins exhibit an NLS 
using the prediction algorithms PredictNLS and Bipartite NLS (Table 10). In this study 
an NLS was detected in ORF4, ORF9, and ORF62 in addition to proteins ORF29 and 
ORF63, which were previously reported to contain an NLS (87,88). Except for ORF9 all 
of these proteins localise in the same compartment both in single cells and syncytia. 
The VZV encoded ORF9 protein localises in the cytoplasm in single cells while in 
syncytia it is found both in the nucleus and cytoplasm. Thus, assuming that single 
cells represent an earlier infection compared to syncytia, the ORF9 protein might be 
translocating from the cytoplasm to the nucleus at a later stage of infection. Proteins 
that carry an NLS have the potential to be actively imported into the nucleus using 
the importin alpha driven classical pathway (89). So far, for VZV ORF29 and ORF63, 
investigators have identified an NLS that is responsible for nuclear localisation (for 
references see Table 10). Stallings and Silverstein have found that an NLS within 
ORF29 is responsible for its transport into the nucleus in a Ran-, Karyopherin alpha- 
and beta-dependent mechanism 70. In ORF63 a predicted NLS localised between 
residues 260 and 263 may be responsible for transport of the protein to the nucleus 
(88). While for ORF4 and ORF62 bipartite NLSs were predicted (Table 10), 
researchers have shown that translocation of these proteins into the nucleus may not 
depend on these NLSs but also be supported by viral interaction partners (52,77). 
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Table 10: Nuclear localisation sequences of VZV encoded proteins 
Protein NLS Amino acid 
position 
Type of 
prediction/Ref. 
ORF4 RRSSRSYNTQSSRKHRD 
RKHRDRSLSNRRRRP 
130 - 144 
118 - 134  
bipartiteNLS 
predictNLS 
ORF9 RRKTTPSYSGQYRTARR 16 – 32 bipartiteNLS 
ORF29  9 - 154 
176 
ORF62 RRFGPPSGVEALRRRCA 395 - 412  bipartiteNLS 
ORF63 KRRR 778 – 789 187 
http://cubic.bioc.columbia.edu/predictNLS/ (NLS) 
http://www.expasy.org/cgi-bin/nicedoc.pl?PDOC00015 (bipartite NLS) 
 
Many proteins that enter the nucleus are equipped with sequences that drive their 
active nuclear export. One of the best characterized signals is the leucine-rich 
nuclear export sequence (NES) that is predicted for a number of VZV proteins (Table 
11). A NES was identified in 14 proteins, ORFs 4, 6, 10, 21, 27, 29, 32, 33, 47, 48, 
55, 62, 64, 66. Of those, the VZV proteins ORF6, 10, and 33 showed a steady state 
localization in the nucleus while all other ORFs are distributed throughout the cell. 
Subcellular localisation of ORF21, ORF27 and ORF32 varies in single cells and 
syncytia. These findings are consistent with shuttling of these proteins between both 
compartments and their behaviour might be regulated. These observations provide 
starting points for a detailed analysis of nucleocytoplasmic trafficking of VZV proteins 
in the course of infection. 
 
Table 11: Nuclear export sequences of VZV encoded proteins 
Protein NES Reference 
ORF4 LGPFVRCLLL (90) 
ORF6 LQAIKDLFL (90) 
ORF10 LARLLYLHLYL 176 
ORF21 LPGLLFWRLDL www.cbs.dtu.dk 
ORF27 LSGMGYHLGL www.cbs.dtu.dk 
ORF29 LAVVQDLAL www.cbs.dtu.dk
 
ORF32 ISLALEI www.cbs.dtu.dk
 
ORF33 LSPLERALYL www.cbs.dtu.dk
 
ORF47 LLGRLPGQLPI www.cbs.dtu.dk
 
ORF48 LSGYFPALKL www.cbs.dtu.dk
 
ORF55 LCWFKQLLEL www.cbs.dtu.dk
 
ORF62 LAALSNRLCL www.cbs.dtu.dk
 
ORF64 LELSERLIL www.cbs.dtu.dk
 
ORF66 LWTNLYELPI www.cbs.dtu.dk 
http://www.cbs.dtu.dk/services/NetNES/ 
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5.5 Comparative analysis 
The available published results on localisation of VZV proteins were in clear 
agreement with our studies except for three VZV encoded proteins (ORF 37, ORF60, 
ORFS/L). In our observation all four VZV encoded proteins were detected in the 
nucleus instead of the cytoplasm. The ORF37 and ORF60 encode glycoproteins gH 
and gL which based on their function are expected to be localised at the ER, Golgi or 
in the plasmamembrane. Many groups have studied gH and gL thoroughly and 
reported their localisation to cytoplasmic membranes which is in complete contrast to 
our observation (66,57). ORFS/L was previously shown to be a cytoplasmic protein 
while we observed it in the nucleus (80). These discrepancies might be caused by 
mishandling of hybridoma clones, antibodies or false detection in ELISA due to cross 
reactivity. 
We have also observed minor differences for two other proteins encoded by ORF20 
and ORF25. Specifically, ORF20 and ORF25 were found only in the cytoplasm by 
other investigators, whereas in our study these two proteins were detected in both 
the nucleus and the cytoplasm (58,63). Interestingly, in the reported analysis 
transfection expression of the specific ORFs was done while in our case VZV 
infected cells were analysed. Thus, the difference could be due to altered expression 
in these studies or due to the lack of viral interaction partners. It is well understood 
that ORF20 encodes for a capsid protein which can be found in both the cytoplasm 
and nucleus. Yeast-2 hybrid analysis showed that VZV ORF25 interacts with 15 other 
VZV encoded proteins and may form functional complexes. Indeed, Visalli and 
colleagues showed that ORF25 forms a complex with ORF30, ORF42 and ORF45 
(63). These studies give clear evidence that ORF25 brings viral proteins together and 
forms a functional network. So, these published observations are consistent with the 
pan-cellular distribution of ORF20 and 25 we observed in our study. Taken together, 
our study provides new localisation data for 22 ORFs which accounts to 32% of the 
VZV genome. By combining the published data with our localisation data the 
intracellular localisation for 57 VZV (81%) encoded proteins could be determined 
(Figure 27). 
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Figure 27: Schematic diagram of intracellular localisation in respect of the viral genome. All 
VZV encoded proteins are shown. The arrows indicate the transcriptional orientation of ORFs in the 
genome. Genes are colour coded as indicated in the figure.  
 
5.6 Comparison of subcellular localisation of herpesviral proteins 
Herpesviruses are subdivided into three different subfamilies based on the genomic 
composition and biology (91,32). They possess dsDNA genomes ranging from the 
smallest 120kbp of the VZV to 240kbp of CMV(32). In all three subfamilies, 41 core 
orthologs are thought to be conserved comprising half of the genome of HSV-1, VZV, 
EBV, and KSHV but less than 25% of CMV. They are further subdivided into a group 
of 31 orthologs with relatively high sequence similarity (approximately 30 to 60% 
sequence similarity), and a group of 10 orthologs with little sequence similarity 
(approximately 16 to 30%) (81). These herpesviral core orthologs are generally 
involved in fundamental aspects of viral replication like entry, DNA replication and 
packaging, structure and primary and secondary envelopment (92,93). 
Nowadays, systems biology approaches are used as a powerful tool to analyse and 
understand complex biological processes of different pathogens (93,94,95). By using the 
yeast-2 hybrid system, Uetz et al. have studied protein-protein interactions in VZV 
and HHV-8 in a proteome-wide fashion (82). Fossum et al. have compared protein 
interaction networks of core orthologs for 5 different human herpesviruses (HSV-1, 
VZV, CMV, EBV, KSHV) (81). The usefulness and validity of such systems biology 
 96 
approaches was supported by subcellular co-localization of HHV-8 proteins K10 and 
its interaction partners previously identified using the yeast-2 hybrid system (82),(96). 
Sofar, the subcellular localisation of proteins derived of 4 herpesviruses (HSV-1, 
CMV, EBV and KSHV) covering 3 herpesviral subfamilies was analysed. In this 
study, we compared the subcellular localisation of 41 core proteins of 5 different 
herpesviruses (HSV-1, VZV, CMV, EBV, KSHV). Our comparative results of 41 core 
proteins conserved in 5 different herpesviruses are shown in Table 12. We have 
classified the subcellular localisation as nuclear, cytoplasmic or both nuclear and 
cytoplasmic. If the interaction between core proteins is conserved they are likely to be 
found in the same compartment. The data received here on subcellular localization 
should in near future be compared to the interaction data received by yeast-2 hybrid 
analysis for VZV. Since the subcellular localisation of a protein is closely associated 
with its function, the subcellular localisation screening is an appropriate starting point 
to characterise the function of so far poorly analysed VZV proteins as well as other 
herpesviral proteins during viral infection. 
For all transmembrane glycoproteins conserved throughout the herpesviral family, we 
localised them in the cytoplasm and to cytoplasmic membranes consistent with their 
biosynthesis at the endoplasmatic reticulum and maturation in and transport along 
the secretory pathway. The interaction between gH:gL and gM:gN is conserved in all 
3 subfamiles. For VZV tegument proteins supposed to function in either nucleus or 
cytoplasm depending on the envelopment step a cytoplasmic and/or nuclear 
localization is expected. A good agreement is seen for VZV ORFs 40 and 41 and all 
orthologues compared in Table 10 since all of them localized to the nucleus and / or 
the cytoplasm, compartments that are in continuous exchange. The same is true for 
the subcellular localisation of capsid proteins compared between all 5 herpesviruses. 
Although their localization is not identical when comparing a set of five orthologs, it 
shows a great amount of similarity between all herpesvirus subfamilies. In 
conclusion, all over there is excellent agreement in localization when core orthologs 
are compared. Of the 32 VZV core orthologs studied, all showed a good match in 
localization with their functional relatives in other herpesviral subfamilies. 
 
Table 12: Subcellular localisation of 41 herpesvirus core proteins 
The colors in the table represents different types of proteins. The blue color represents glycoproteins, 
red represents for capsid proteins and pink for tegument proteins. 
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VZV and HSV-1 share 65 orthologs and for 39 proteins information on their 
subcellular localization is available either from the literature or our own results (Figure 
28). Our data show that 35 out of 39 orthologs (90%) show a similar localization. Out 
of these, 21 orthologs show complete identity in subcellular localisation while 14 
orthologs localize similarly. So, comparing the subcellular localisation of orthologs of 
VZV 
(ORF) 
Locali 
sation HSV-1 
Locali 
sation CMV  
Locali 
sation KSHV  
Locali 
sation EBV  
locali 
sation 
          
ORF4 N&C UL54  N UL69  57 N BMLF1 N 
ORF6 N UL52 C UL70  56 C BSLF1 C 
ORF7 C UL51 N&C M71  55  BSRF1  
ORF8 N&C UL50 N&C UL72  54 N BLLF3 N 
ORF9a  UL49.5 C M73 C 
(97)
 53 C BLRF1  
ORF 16 N&C UL42 N UL82  59  BMRF1  
ORF 19 C UL39  UL45 XX 61 C BORF2  
ORF 20 N&C UL38  N M46  62  BORF1  
ORF 21 N&C UL37 C US29 N 63  BOLF1  
ORF 22 C UL36  C
(98)
 UL48  64 C BPLF1  
ORF 23 N&C UL35 N&C M48.2  65  BFRF3  
ORF 24 N UL34 N&C UL50 C 67 C BFRF1 C 
ORF 25 N&C UL33 N&C UL51 N&C 67.5 C BFRF4  
ORF 26 N UL32 C UL52  68 C BFLF1  
ORF 27 C UL31 N&C UL53 N 69 N BFLF2 N 
ORF 28 C UL30 N&C UL54  9 C BALF5  
ORF 29 N UL29  N&C UL57  6 N BALF2 N 
ORF 30 N&C UL28  UL56 N&C 7 N&C BALF3  
ORF 31 C UL27 C 
(99)
 UL55 
C 
(100,101)
 8 C BALF4 
   C 
(102,103)
 
ORF 33 N UL26 N UL80 N 17 N BVRF2  
ORF 33.5 N UL26.5  M80.5  17.5  BdRF1  
ORF 34  UL25 N&C UL77 C 19 N&C BVRF1  
ORF 35  UL24 N UL76  20 N BXRF1  
ORF 37 C UL22 C 
(104,73)
 UL75 C 22 C 
(105)
 BXLF2    C  
(106)
 
ORF 38  UL21 N&C M88  23  BTRF1  
ORF 40 C UL19 C UL86 C 25 C BCLF1  
ORF 41 C UL18 N&C UL85 N&C 26 N&C BDLF1 N&C 
ORF 42  UL15  UL89  29b N&C BDRF1 N&C 
ORF 43  UL17  UL93 N&C 32 N&C BGLF1 C 
ORF 44 N&C UL16 N&C UL94 N&C 33 N BGLF2 N&C 
ORF 46  UL14 N&C 
(107)
 M95  34  BGLF3  
ORF 47 N&C UL13 C UL97  36 N BGLF4 N&C 
ORF 48 N UL12 C UL98 nuc 37 N BGLF5  
ORF 49 C UL11  M99  38  BBLF1  
ORF 50 C UL10 C 
(72)
 UL100 C  
(97)
 39 C BBRF3  
ORF 52  UL8 
(108)
 M102  40  BBLF2  
ORF 53 C UL7 
(108)
 UL103 C 42 N&C BBRF2 N&C 
ORF 54  UL6  UL104  43 C BBRF1 C 
ORF 55 N UL5  UL105  44 C BBLF4 N&C 
ORF 59 N&C UL2  UL114 N&C 46 N&C BKRF3 N&C 
ORF 60 C    UL1 C 
(74,73)
 M115 
C 
(109,110)
 47 C 
(111,105)
 BKRF2  
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herpes viruses will provide good information to study functions of unstudied orthologs 
and their interaction partners. 
 
 
 
Figure 28: Comparison of the subcellular localisation of VZV and HSV-1 orthologs. The 
subcellular localisation was represented by specific colors shown in the figure. Identical subcellular 
localisation of VZV and HSV-1 orthologs was highlighted by the boxes present between ORF numbers 
(modified from 
(112)
).  
 
5.7 Epitope mapping  
Herpesvirus glycoproteins are part of the virus outer envelope that is responsible for 
inducing B-cell based immune response and are widely used as serological agents. 
The antibodies against viral glycoproteins play a major role in neutralisation and 
immune defence of the host. Previously, for many herpesviral glycoproteins epitope 
mapping was done using the pepscan technique to identify their antigenic 
determinants (113). In our study the same method was applied to identify several 
immunodominant regions for the viral glycoproteins gK, gB, gL, gI, gE and the 
membrane-associated phosphoprotein ORF24.  
The positive clones 6B11 and 5A6 specific for gK identified five immunodominant 
regions. Antibodies produced by clone 6B11 detected five discrete stretches of 
aminoacids, 18GHAVFTLWYTAR31, 96TPLHDKIRI106, 135QFRRIR142, 
156TSYSLNYVTRVISNILLGYPY178 and 195KVFNADPISFLYMHK210. MAbs from clone 
5A6 also identified five different discrete stretches. The identified residues are 
90VKTAISTPLHDKIRI106, 135QFRRIR142, 168SNILLGYPYTKL181, 195KVFNADPISFL-
YMHK210 and 264LISYVRPKPTKDNHL279. Two very similar immunodominant regions 
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are recognized by both monoclonal antibodies, 135QFRRIR142 and 
195KVFNADPISFLYMHK210, an overlap between two other sequences in residues 
96TPLHDKIRI106 and 168SNILLGYPY178 was observed. These observations suggest 
that these regions in gK are highly immunogenic. 
The clones 2A7 generated against gB and 5E5 generated against gL detect a long 
continuous stretch at the C-terminal end of each immunogen, 
831ARKKNKTSALLTSRLTGLALRNRRGYSRVR862 in gB and 77KCPVPEVILWFK-
DKQMAYWTNPYVTLKGLAQSV111 in gL. The mAbs 3D6 made against gI identified  
three discrete stretches at the C-terminal end of gI and IYR is the common epitope 
region recognised by the first two stretches. The mAbs 6B12 recognised eight 
discrete stretches from the complete antigenic region and 
282PGVLKVLRTEKQYLG298 is the common epitopic region recognised by reactive 
spots 5 and 6. 
The mAbs 1G11 and 3B7 raised against the membrane phosphoprotein ORF24 
recognise seven and three discrete stretches in the N-terminal region. Both mAbs 
identify one common immunodominant region, 153NCFVRMPYVQLSFRF169 and two 
regions with a partial overlap, 15GDNLLQRIR25 and 195NLDEYIRWR205. The detection 
of common immunodominant regions in both clones shows that these regions are 
antigenic and elicit B cells to produce antibodies. 
From these observations it can be concluded that the antibodies to gB and gI 
recognize linear epitopes while antibodies to gK, gL, gE and ORF24 have complex, 
conformational epitopes. It should be noted however, that the pepscan technique is 
biased towards detection of short linear stretches of aminoacids (114). So, the 
antibodies we have tested could recognize additional more complex epitopes in the 
protein that cannot be identified by the pepscan technique.  
Monoclonal antibodies could potentially be used for neutralization of VZV infection. 
Researchers have indeed identified antibodies that are capable to neutralise VZV 
virions by binding to the surface proteins gH and gE (115,116). The identification of 
immunodominant regions by epitope mapping is an initial step to characterise our 
mAb clone collection. This characterisation will help to perform further analysis to 
identify additional neutralising monoclonal antibodies and the regions within VZV 
proteins targeted by these antibodies. 
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7. Abbreviations 
 
 micro (10-6) 
°C degrees Celsius 
Apr ampicillin resistence 
ATP adenosine triphoshate 
bp base pair 
BSA bovine serum albumin 
C. elegans Caenorhabditis elegans 
cDNA complementary DNA 
CDR complementary determining region 
Cmr chloramphenicol resistence 
CMV Cytomegalovirus 
CNS Central Nervous System 
CVS congenital varicella syndrome 
C centigrade 
C cytoplasm 
DAPI 4-6 diamidino-2-phenylindole 
DHFR dihydrofolate reductase 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleoside triphosphate 
DRG dorsal root ganglia 
ds double stranded 
DTT dithiothreitol 
E early 
E. coli Escherichia coli 
e.g. exempli gratia (Lat. = for instance) 
EBV Epstein-Barr-Virus 
EDTA ethylene-diamine-tetraacidic acid 
EHV equine herpesvirus type 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmatic reticulum 
et al. et alii (Lat. = and others) 
EtOH ethanol 
FA formaldehyde 
Fab fragment antibody binding 
FC fragment crystallizable 
FCS fetal calf serum 
FISH fluorescent in situ hybridization 
FL full length 
g gram 
GC Guanine and Cytosine 
Gmr gentamycin resistence 
h hour(s) 
H heavy 
HA hemagglutinin 
HAT Hypoxanthine Aminopterin Thymidine 
HCl hydrochloric acid 
HCV hepatitis C virus 
HHV human herpesvirus 
HIS histidine 
HIV human immundeficiency Virus 
HSV Herpes simplex virus 
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HVS herpesvirus saimiri 
HZ Herpes zoster 
IE immediate-early 
ISH in situ hybridization 
kbp kilobasepairs 
kDa kilo Dalton 
Kmr kanamycin resistence 
KSHV Kaposi’s sarcoma-associated herpesvirus 
L late 
L light 
l litre 
IDE insulin-degrading enzyme 
IF immunofluorescence 
LB Luria Bertani medium 
LEU leucin 
m milli (10-3) 
Mab monoclonal antibody 
Man-6-P mannose-6-phosphate 
MBP Maltose-binding protein 
MCD multicentric Castleman’s diseases 
MCP major capsid protein 
MHC major histocompatibility complex 
min minute(s) 
mRNA messenger RNA 
MW molecular weight 
Mw mother well 
n nano (10-9) 
N nuclear 
NLS nuclear localization signal 
Neg negative 
NES nuclear export signal 
NT not tested 
OD optical density 
ORF open reading frame 
PBS phosphate buffered saline  
PCR polymerase chain reaction 
PEG polyethylene glycol 
PEL primary effusion lymphoma  
PHN Postherpetic neuralgia 
PMBC peripheral blood mononuclear cells 
p-OKA parental OKA 
pos positive 
PRV pseudorabies virus 
RC recombinatorial cloning 
Ref reference 
RNA ribonucleic acid 
RNAi RNA-mediated interference 
rpm revolutions per minute 
RT room temperature 
s second(s) 
S. cerevisiae Saccharomyces cerevisiae 
SCID Severe combined immunodeficiency 
S. aureus Staphylococcus aureus 
SDS sodium dodecylsulfat 
SOC Super optimal broth 
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ssDNA single-stranded DNA 
TEMED tetramethylethylendiamin 
TG trigeminal ganglia 
TGN trans-Golgi network 
TK thymidine kinase 
TPA tissue plasminogen activator 
TRP tryptophan 
TS thymidylate synthase 
UL unique long 
US unique short 
UV ultraviolet 
VZV varizella zoster virus 
WB western blot 
w/o without 
Y2H yeast two-hybrid 
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